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1.  Introduction 
 
Aortic and mitral valve diseases are progressively increasing in the Western world, affecting 
an increasing number of patients. Data from the STS database, the voluntary database that 
collect data from the vast majority of the USA cardiac surgical centers have shown a steed 
increase in the surgical procedures done for these two pathologies. 
 
 
 
 
 
 
From 2001 and 2010, there has been a significant increase for isolated aortic valve 
replacement (AVR) (from 9656 to 25219 cases) for mitral valve repair (MVRep) (from 2.755 
to 7.207 cases), and this is also true for mitral valve replacement (MVR), AVR + CABG, and 
MVRep + CABG. 
This epidemic of valve disease is due in part to ageing population of Western countries but 
also to some unknown factors. 
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In this thesis we will analyze the molecular mechanisms of aortic valve stenosis and mitral 
valve prolapsed, the possible surgical implications and linking and the role of oxidative stress 
as a potential main factor in the occurrence and progression of these diseases. 
 
 
2.  Aortic valve stenosis: molecular mechanisms and 
targeted preventive therapies  
 
2.1 Anatomy of the aortic valve 
 
The aortic valve is a semilunar valve that is quite similar morphologically to the pulmonary 
valve. Likewise, it does not have a discrete annulus. Because of its central location, the aortic 
valve is related to each of the cardiac chambers and valves. The aortic valve consists 
primarily of three semilunar leaflets. As with the pulmonary valve, attachments of the leaflets 
extend across the ventriculoarterial junction in a curvilinear fashion. Each leaflet therefore has 
attachments to the aorta and within the left ventricle. The leaflets themselves meet centrally 
along a line of coaptation, at the center of which is a thickened nodule called the nodule of 
Arantius. Peripherally, adjacent to the commissures, the line of coaptation is thinner and 
normally may contain small perforations. During systole, the leaflets are thrust upward and 
away from the center of the aortic lumen, whereas during diastole, they fall passively into the 
center of the aorta. With normal valvar morphology, all three leaflets meet along lines of 
coaptation and support the column of blood within the aorta to prevent regurgitation into the 
ventricle. Behind each leaflet, the aortic wall bulges outward to form the sinuses of Valsalva.  
Two of the three aortic sinuses give rise to coronary arteries, from which arise their 
designations as right, left, and noncoronary sinuses.  
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The aortic root, representing the outflow tract from the left ventricle, provides the supporting 
structures for the leaflets of the aortic valve, and forms the bridge between the left ventricle 
and the ascending aorta. The root itself, surrounding and supporting the leaflets, has length in 
that it extends from the basal attachments of the leaflets within the left ventricle to the 
sinutubular junction. The discrete anatomic ventriculoaortic junction is a circular locus within 
this root, formed where the supporting ventricular structures give way to the fibro-elastic 
walls of the aortic valvar sinuses. This discrete ring, however, is markedly discordant with the 
morphology of the attachment of the leaflets of the aortic valve. Indeed, it is crossed at several 
points by the hingelines of the valvar leaflets. These lines, semilunar in structure, extend 
throughout the root, running from their basal attachments within the left ventricle to their 
distal attachments at the sinutubular junction. The root as thus defined, therefore, is a 
cylinder, its walls being made up of the aortic valvar sinuses along with the interdigitating 
intersinusal fibrous triangles, and with two small crescents of ventricular muscle incorporated 
at its proximal end. It is the semilunar attachments of the leaflets within the valvar sinuses 
that form the haemodynamic junction between the left ventricle and the aorta. All structures 
on the distal side of these attachments are subject to arterial pressures, whereas all parts 
proximal to the attachments are subjected to ventricular pressures. In functional terms, all 
three sinuses of the root, and their contained leaflets, are identical. Anatomically, however, it 
This section through the heart, 
replicating the parasternal long axis 
echocardiographic cut, shows how the 
aortic root is the centrepiece of the heart. 
The root extends from the basal 
attachments of the valvar leaflets within 
the ventricle (yellow arrows) to the 
sinutubular junction (red dotted line). The 
compass shows the orientation relative 
to the remaining thoracic organs. 
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is necessary to distinguish between the three components. This is best achieved by noting that 
two of the valvar sinuses give rise to the coronary arteries. These can be nominated as the 
right and left coronary aortic sinuses. These two sinuses, for their greater part, are made up of 
the aortic wall. But, because the semilunar attachments of the leaflets cross the anatomic 
ventriculoaortic junction, a crescent of ventricular musculature is incorporated at the base of 
each of these two sinuses. The third sinus does not give rise to a coronary artery, and hence, 
can be designated as the non-coronary aortic sinus. There is no muscular crescent at the base 
of this sinus, since this sinus has exclusively fibrous walls, the basal part beneath the 
anatomic ventriculo-aortic junction being part of the important continuity between the leaflets 
of the aortic and mitral valves that is a feature of the outflow tract of the left ventricle. The 
areas between the basal attachments of the aortic sinuses within the ventricle itself, which 
extend distally to the level of the sinutubular junction, are triangular extensions of the left 
ventricular outflow tract. They are thinned fibrous areas of the aortic wall. 
 
 
 
Removing these triangular extensions puts the most distal parts of the left ventricle in direct 
communication either with the pericardial space or, in the case of the triangle between the two 
coronary aortic valvar sinuses, with the fibroadipose plane of tissue between the back of the 
subpulmonary infundibulum and the front of the aorta.  The triangle between the left coronary 
and the noncoronary aortic valvar sinuses is part of the extensive curtain of aortic-to-mitral 
The aortic root has been opened from behind 
and spread apart, so that the full width of the 
cylinder can be seen. The aortic valvar leaflets 
have then been removed, revealing the 
semilunar nature of their attachments. The 
purple dotted line shows the anatomic 
ventriculo-aortic junction, which is the union 
between the ventricular musculature and the 
aortic wall at the bases of the left and right 
coronary aortic valvar sinuses (#1, #2), but 
between the aortic wall and fibrous continuity 
with the mitral valve at the base of the non-
coronary sinus (#3). Note how the semilunar 
attachments 
incorporate muscle at the base of the 
coronary aortic sinuses, but fibrous tissue 
within the ventricle as the hingelines extend 
distally to reach the sinutubular junction (red 
dashed triangle). 
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valvar fibrous continuity. This triangle, when removed, creates a window to the transverse 
pericardial sinus, the latter being the space between the back of the aortic root and the anterior 
atrial walls. The triangle between the non-coronary and the right coronary aortic valvar 
sinuses is directly continuous with the membranous part of the ventricular septum. The basal 
part of this fibrous wall is crossed on its right side by the hinge of the tricuspid valve, dividing 
the membranous septum itself into atrioventricular and interventricular components. The 
apical part of the triangle extends to the sinutubular junction. Removal of this part creates a 
window between the left ventricular outflow tract and the right side of the transverse 
pericardial sinus, opening externally above the attachment of the supraventricular crest of the 
right ventricle. The third triangle, which separates the two coronary aortic valvar sinuses, is 
the least extensive of the three. To show the location of this triangle, it is first necessary to 
remove the free-standing muscular subpulmonary infundibulum. Once this has been done, 
then it can be seen that removal of the triangle itself creates a window between the subaortic 
outflow tract and the plane of tissue which separates the aortic root from the infundibulum. 
The semilunar attachment of the valvar leaflets, therefore, divides the aortic root into 
supravalvar and sub valvar components. The supravalvar components, the aortic sinuses, are 
primarily aortic in structure, but contain structures of ventricular origin at their base. The 
supporting subvalvar parts are primarily ventricular, but extend as thin-walled fibrous 
triangles to the level of the sinutubular junction. The sinutubular junction itself forms the 
discrete distal boundary of the root. The valvar leaflets are attached peripherally at this level, 
and hence, the junction is an integral part of the valvar mechanism. Any significant dilation at 
the level of the sinutubular junction will produce valvar incompetence. It is moot, therefore, 
whether stenosis at this level should be labelled as ‗supraaortic‘, since the sinutubular junction 
is just as crucial a component of the overall valvar mechanism as are the leaflets and their 
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supporting sinuses. Anatomically, the sinutubular junction is no more than the distal extent of 
the overall valvar complex. 
 
 
When viewed in attitudinally correct orientation  the aortic root is positioned to the right and 
posterior relative to the subpulmonary infundibulum. The subpulmonary infundibulum itself is 
a complete muscular funnel, supporting in uniform fashion the leaflets of the pulmonary 
valve. The leaflets of the aortic valve, in contrast, are attached only in part to the muscular 
walls of the left ventricle, since so as to fit the orifices of both aortic and mitral valves within 
the circular profile of the left ventricle, there is no muscle between them in the ventricular 
roof. The aortic root, furthermore, is wedged between the orifices of the two atrioventricular 
valves. The root is related to all four cardiac chambers. These relationships can be well 
recognised in the clinical situation. The proximity of the root to the anterior interatrial groove 
is now appreciated by those who have inserted devices via catheters to close defects of the 
oval fossa, only to find the arms of the devices eroding into the aorta. The relationship to the 
subpulmonary infundibulum is well demonstrated by the spread of bacterial infection from the 
valve, or by aneurysmal dilation of the right coronary aortic sinus of Valsalva. The most 
The heart has been dissected by 
removing the atrial chambers and the 
arterial trunks, and is photographed 
from above, looking down on the 
atrioventricular and ventriculo-arterial 
junctions. It is orientated as it may be 
seen by the surgeon. The dissection 
shows how two of the aortic valvar 
sinuses (#1, #2) give rise to coronary 
arteries, and can be nominated as 
the left and right coronary aortic 
sinuses, respectively. The third sinus 
(#3) does not give rise to a coronary 
artery, and hence, is the non-
coronary aortic sinus. Note again that 
the aortic valve forms the cardiac 
centrepiece. 
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important surgical relationship, nonetheless, is probably to the atrioventricular node and the 
penetrating atrioventricular bundle. The node, located in the wall of the right atrium at the 
apex of the triangle of Koch, is relatively distant from the root. As the conduction axis 
penetrates through the central fibrous body, however, it is positioned at the base of the 
interleaflet triangle between the non- and right coronary aortic sinuses. Having penetrated 
through the fibrous plane providing atrioventricular  insulation, the bundle then branches on 
the crest of the muscular ventricular septum, the left bundle branch fanning out on the smooth 
left ventricular side, whilst the cord-like right bundle branch penetrates back through the 
muscular septum, emerging on the septal surface in the environs of the medial papillary 
muscle. In this position, therefore, the muscular axis responsible for atrioventricular 
conduction should be relatively distant from most surgical manoeuvres carried out to replace 
or repair the aortic valve and its supporting structures. 
 
 
 
 
 
 
 
 
 
The cartoon shows the location of 
the atrioventricular conduction axis 
as it would be seen by the surgeon 
looking down through the aortic root. 
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2.2 Pathophysiology of aortic valve stenosis 
 
Similarities in risk factors strongly suggest that a similar process underlies both the 
development and progression of calcific AS as well as atherosclerosis. Risk factors shared by 
calcific AS and atherosclerosis include hypertension, elevated LDL cholesterol, male gender, 
smoking, and diabetes mellitus. Epidemiological evidence consistent with these similarities 
includes the occurrence of valvular heart disease in patients with homozygous familial 
hypercholesterolaemia, a condition characterised by profoundly elevated LDL cholesterol and 
premature development of atherosclerosis as well as the connection between aortic valve 
sclerosis and cardiovascular mortality and morbidity in elderly patients; there is an increased 
risk of myocardial infarction and death from cardiovascular causes in patients with AS, even 
among individuals without leftventricular outflow obstruction.   
Palta et al. investigated the clinical, echocardiographic, and biochemical characteristics that 
might bear on the rate of progression of AS in a group of 170 consecutive patients who had 
paired echocardiograms 3 months (23+11) apart. Baseline values were left ventricular outflow 
tract (LVOT) velocity, 0.9+0.2 m/s; peak aortic velocity, 2.7+0.07 m/s; and aortic valve area 
(AVA) 1.17+0.38 cm2. The annual reduction in AVA was significantly related to the initial 
AVA (r = 0.46, P = 0.0001), mean aortic valve gradient (r = 20.27, P = 0.04), LVOT velocity 
(r = 0.26, P = 0.001), and LV end-diastolic diameter (r = 0.20, P = 0.04) and marginally 
related to the baseline serum creatinine level (r = 0.15, P =  0.08). Patients with a serum 
cholesterol level .5.18 mmol/L (200 mg/dL) had an AVA reduction rate that was about two 
times as high as that of patients with lower cholesterol levels (P ¼ 0.04). The investigators 
concluded that, in patients with AS, increased levels of serum cholesterol, creatinine, and 
calcium, as well as current smoking, accelerate the reduction in AVA. Important 
histopathological evidence that calcific AS unfolds in ways similar to those of atherosclerosis 
was reported by O‘Brien et al.,15 who found that apolipoproteins B and E are present in early 
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as well as advanced aortic valve lesions but not in normal valve regions; a similar pattern of 
lipoprotein deposition also occurs in coronary atherosclerosis. Several studies have helped to 
explain the process by which aortic valves become calcified. Mohler et al. demonstrated that 
osteopontin, a protein in bone matrix that regulates the deposition of calcium, is found in 
minimally and severely calcified aortic valves and located mainly in the calcified areas. 
Additional evidence that aortic valve mineralisation is an active biological process, similar to 
that occurring in bone, derives from our study of surgically removed valves, which 
demonstrated an osteoblast phenotype. As shown by reverse transcription–polymerase chain 
reaction (RT–PCR), increased transcription of genes for osteopontin, bone sialoprotein, 
osteocalcin, bonespecific transcriptional factor Cbfa1, and glyceraldehyde- 3-phosphate 
dehydrogenase (GAPDH) (i.e. increased mRNA levels) was evident in calcified (vs. normal) 
aortic valves. 
In addition to increased gene transcription, certain signal transduction mechanisms that are 
upregulated in bone formation also seem to be activated in mineralizing aortic valve leaflets. 
In particular, LDL receptor-related protein 5 (Lrp5), osteocalcin, and other bone markers are 
upregulated in calcified tricuspid and bicuspid aortic valves. In the presence of 
hypercholesterolaemia, the Lrp5 pathway seems to be activated in mesenchymal 
myofibroblast cells within the valve, switching them to a bone-producing phenotype. This 
‗phenotypic switch‘ occurs through the binding of Lrp5 to the glycoprotein Wnt, which in 
turn activates b-catenin to induce the formation of bone. Upregulation of osteogenic bone 
signaling markers may be expressed as cartilage formation in human myxomatous 
(degenerative) mitral valves and calcification in bicuspid and tricuspid valves.  
The pathophysiology of calcific AS is no longer considered to be a largely passive process but 
is rather understood to be an active one, with initiating factors and mechanisms of progression 
that are broadly similar to those of atherosclerosis in coronary and other arteries. Risk factors 
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shared by calcific AS and atherosclerosis include hypertension, elevated LDL cholesterol, 
male gender, smoking, and diabetes mellitus. Calcific AS often develops in persons with 
atherosclerosis, as indicated (especially in the elderly) by an increased risk of deaths from 
cardiovascular disease in patients with calcific AS. In addition, calcific AS and 
atherosclerosis may coexist in persons with homozygous familial hypercholesterolaemia.  
Animal studies have shown that, as in atherosclerosis, experimental hypercholesterolaemia 
initiates endothelial dysfunction in aortic valves, with upregulation of oxidative stress and 
inflammatory processes leading to plaque formation, as well as a switch to an osteogenic 
phenotype with valve mineralisation. Evidence for the presence of endothelial dysfunction in 
the development of calcific AS has been demonstrated in human valves that have been 
removed surgically. In animal studies of AS, administration of a statin blunted 
hypercholesterolaemia- induced valve mineralisation and cellular proliferation. This 
background on AS pathophysiology helps to set the stage for potential benefits of LDL 
cholesterollowering therapy in humans, with the hope that medical therapy may be able to 
prevent or delay the need for valve replacement. Hypercholesterolaemia may be an important 
factor in the initiation and progression of AS, and statins may inhibit the induction of this 
process in animals. If the human aortic valve undergoes a pathophysiological process initiated 
by hypercholesterolaemia with oxidative modification of cholesterol, as suggested by the 
studies described earlier, medical therapy might help to decelerate AS progression. The 
leading indication for surgical valve replacement is calcific AS.  
Evidence of endothelial dysfunction in the development of calcific AS in humans has been 
obtained through the study of surgically excised aortic valves. Appreciation that calcific AS 
reflects the results of active biological processes has led to the consideration that these 
processes may be amenable to elimination or slowing by pharmacotherapeutic intervention, 
potentially avoiding or at least postponing the need for valve replacement. 
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2.3  Non-rheumatic calcific aortic stenosis: an overview from basic 
science to pharmacological prevention 
 
INTRODUCTION 
 
Calcific  aortic valve stenosis is the most common heart valve disease in the Western world, 
especially in elderly people [1, 2];  on average, 50.000 aortic valve replacements every  year 
occur both  in Europe and in the United States due to this pathology, which is the most 
common valvular disease of the adult [3, 4]. The prevalence of clinically significant aortic 
stenosis increases progressively with age: it is around 2% in people over 65 [5], an it is more 
than 4% in octuagenarians [6].  The behavior of aortic valve sclerosis, a milder form of aortic 
valve disease characterized by calcification and stiffening of the aortic valve without a 
transvalvular gradient, parallels the one of calcific stenosis, being the prevalence around 20%-
30%  in patients aged over 65 years [5, 6], and reaching 48%-57% in octuagenarians [6, 7]. 
This translates in very high costs for the health organizations, that are estimated to be around 
1 billion US dollars per year in the United States [1], leading consequently to great  interest in 
medical  therapies that could potentially slower the progression of this disease.  
In recent years, the assumption that calcific aortic stenosis is a passive, age-related disease has 
been strongly questioned by studies showing several similarities and some dissimilarities to 
atherosclerosis in this evolving pathological process and consequently studies investigating 
the potential role of  the most diffuse anti-atherosclerotic drugs, the statins, have been carried 
out with –unfortunately- controversial results. 
In this paper we review the current knowledge on molecular bases of aortic sclerosis and 
stenosis, the potential preventive therapies, and the results coming from recent clinical trials. 
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GENOMICS 
Several genomic studies have assessed the possible association between calcific aortic 
stenosis and genetic factors, concerning mainly atherosclerosis and bone metabolism. About 
atherosclerosis, even if earlier studies have documented a possible link between lipid 
metabolism and progression of aortic valve disease [8], studies evaluating the prevalence of 
apolipoprotein E [9-11],  AI [9],  e B [9] in patients with aortic stenosis have shown 
conflicting results. In patients with calcific aortic stenosis there is  a prevalence of the allele 
X+/X+ of apolipoprotein B, but similar allelic frequencies of A alleles [9], whereas it is 
actually unclear whether apoE allelic variants differ in patients with aortic stenosis from 
controls; some studies have documented higher prevalence of apoE2 [9] and of apoE4 [11] in 
aortic stenosis, but these data have not been confirmed by others [10]. Overall, the question 
whether the frequency of the allelic variants of these lipoproteins is different in aortic stenosis 
with respect to general population remains still unanswered.  
The role of  inflammation has also been deeply investigated. Some polymorphisms of the 
interleuchin-10 gene promoter, namely -1082, -819, -592, are associated to the extent of 
calcium content  of stenotic aortic valves excised during surgical intervention, and the effect 
of these alleles is further potentiated in patients simultaneously carrying the rare chemochine 
receptor 5 and connective tissue growth factor alleles [12].   
Bone metabolism genomics has been investigated through the assessment of vitamin D 
receptor genetic polymorphism (BsmI B/b) [13], that predicts bone density or bone mineral 
mass [14]; patients with aortic valve stenosis show higher frequencies of the B allele, which is 
associated to reduced calcium adsorption, to more rapid bone loss with advancing age, and  to 
higher parathormone levels [13], suggesting that  the bone metabolism profile favoring 
calcium mobilization from bone could promote aortic valve calcification. In addition, it has 
been recently shown that a nonsense mutation of the NOTCH1 gene is associated to early 
19 
 
developmental defects and to late de-repression of calcium deposition causing aortic valve 
disease progression [15]. It is known that NOTCH1 gene plays an important role in hemato-
oncogenesis, in stem cell signaling and in cell differentiation during organogenesis, it can also 
act as a repressor of the transcriptional activity of Runx2 which is important for osteoblast 
activity, and its inhibition may cause a de-repression  of calcium deposition in the aortic valve 
[15]. Preliminary evidence also suggests a possible role in aortic valve calcification process 
for PvuII polymorphism of the alpha estrogen receptor, possibly linked to the prevalence of 
aortic valve calcification in post-menopausal women [16], likely though an increase of 
cholesterol [16].   
Finally, some cell cycle regulatory genes may contribute to calcific aortic disease progression, 
as it has been shown that the expression of p21
WAF1/CIP1
 (cyclin-dependent protein-chinase 
inhibitor p21), and of  14-3-3 σ  genes is reduced, both at a transcriptional and translational 
level, in calcific aortic valves [17]. This points to cell cycle control as an attractive potential 
target for future therapies aimed at reducing the progression of aortic valve disease, although 
evidence up to date suggests that only bone metabolism polymorphisms have a definite role in 
the progression of aortic valve disease and the role of  lipid metabolism genomics and of cell 
cycle regulation is still at the hypothesis level. 
 
ATHEROSCLEROSIS 
The development and progression of calcific aortic stenosis is an active atheroinflammatory 
process consisting of local inflammatory components and deposition of plasma lipoproteins in 
the lesions; this process shares several features with atherosclerosis with –however- some 
important differences.   
Initial lesions of aortic valve disease are quite similar to atherosclerosis by nature and include 
disruption of the basement membrane, subendothelial accumulation of intracellular lipids and 
lipoproteins, and infiltration of foam cells, nonfoam cells, and T lymphocytes, together with 
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local and systemic activation of inflammation [2, 18]. On the other hand, calcification is more 
extensive in aortic valve disease than in atherosclerosis, and fibrocalcific thickening is 
responsible for the clinical manifestations of the disease [19, 20]. In this section we resume 
the studies which have addressed the possible relation between aortic valve disease (sclerosis 
and stenosis) and atherosclerosis. 
 
Endothelial function. Patients with aortic valve sclerosis have impaired endothelium-
dependent, post-ischemic, flow-mediated dilation [21]; in addition, aortic valve sclerosis is 
associated with higher intima-media thickness, a marker of early atherosclerotic vascular 
structural changes [22], with respect to normal subjects [23]. This further confirms and 
extends the current concept that relates aortic valve sclerosis, atherosclerosis, and increased 
risk of future cardiovascular events for patients affected by valve sclerosis [24-27].  
Endothelial damage in patients with calcific aortic valve disease is further supported by the 
demonstration of increased E-selectin plasma levels in patients affected by severe aortic 
stenosis which return to normal after surgery [28]. The evidence showing higher circulating 
levels of endothelial microparticles that are correlated with the number of activated 
monocytes  [29], provides another link between aortic disease and atherosclerosis. Finally, 
studies performed on aortic valve specimens collected at intervention time have shown that 
diseased aortic valves express more markedly several endothelial markers such as CD31, 
CD34, von Willebrand factor, and CEACAM1 (carcinoembryonic antigen-related cell 
adhesion molecule), with respect to normal valves [30], further supporting the association 
between endothelial dysfunction and calcific aortic valve disease progression.   
Lipid metabolism. Among traditional risk factors for atherosclerosis, lipid metabolism 
abnormalities have been frequently associated with calcific aortic valve disease. In 1994 Otto 
et al. described the possible links between lipid metabolism and calcific aortic disease 
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showing, in diseased aortic valves, the presence of large amounts of intracellular and 
extracellular neutral lipids that could not be found in normal valves [27]; since then, 
hyperlipemia has been widely investigated as a possible mechanism underlying aortic valve 
stenosis development and progression, and several studies support a strong association 
between lipid metabolism and aortic valve disease. It has been recently shown that plant 
sterols accumulate in stenotic aortic valves in a direct relation to their respective serum 
concentrations [31]; this is a proof of concept that lipid metabolism is strictly related to the 
development and progression of aortic valve disease, as it clearly demonstrates that 
circulating lipids are capable of entering in aortic valve leaflets and thus to exert local effects 
in the interstitium of  aortic valves. In addition,  angiotensin converting enzyme co-localizes 
with circulating LDL and apolipoprotein B in sclerotic and stenotic aortic valves [32], 
suggesting that  angiotensin converting enzyme may be concentrated in aortic lesions through 
the retention of plasma lipoproteins. Moreover, stenotic aortic valves contain increased levels 
of  low-density lipoprotein receptor-related protein-5 (LRP5) [33],  a member of the low-
density lipoprotein receptor–related proteins family of cell-surface receptors that are involved 
in diverse biologic
 
processes, including lipid metabolism, retinoid uptake, and
 
neuronal 
migration;  LRP5 plays an important role in the activation of skeletal bone development and 
in the differentiation process of aortic valve mesenchimal myofibroblasts into osteoblasts, 
providing another link between lipid metabolism and aortic valve calcification [33].  
Additional evidence suggesting a strong relation among lipid metabolism, atherosclerosis and 
aortic valve disease comes from the post-mortem analysis of the aortic valve of a 7-years old 
boy who died in  the 50‘s because of type IIb familial hypercholesterolemia; even in this 
young boy, atherosclerotic lesions with plaques rich in lipid-laden foam cells, focal areas of 
collagen and scant basophilic round substances were found in aortic valve tissue[34].  
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From a clinical standpoint, studies have also addressed the potential role of atherosclerosis 
risk factors in the development and progression of calcific aortic stenosis, showing that high 
LDL and lipoprotein (a) levels are risk factors both for aortic valve sclerosis [6, 35, 36] and 
for stenosis as well [37], even if recent studies limit that effect to patients less than 65 years 
old [38]. In addition, it   has also been shown that  metabolic syndrome  is associated with 
aortic stenosis progression over time and this can be explained in great part by the fact that 
patients  affected by metabolic syndrome had greater LDL cholesterol levels than controls 
(124 mg/dL vs. 85 mg/dL) [39]. Hypercolestherolemia as a causative factor for aortic valve 
disease is not a new concept, as in 1997 Wilmshurst et al sowed that patients suffering from 
aortic valve stenosis had higher total cholesterol levels [8]; more recently, Pohle et al have 
documented that hypercolesterolemic subjects (LDL > 130 mg/dL) have much greater 
progression of aortic valve calcifications over time, with an average annual increase of 
calcium of 43% vs. an increase of 9% in controls (p<0.001) [40]. Besides LDL, the overall 
lipid profile seems to play a role in aortic valve disease, as not only high LDL levels but also 
high total cholesterol, low HDL levels, and an higher total cholesterol/HDL ratio are 
independently associated to higher progression rates [41]; also particle size affects 
progression of aortic valve disease, since small circulating LDL  particles (< 255 Angstrom) 
are increased in patients with faster disease progression [42]. This could be related to greater 
accumulation of oxidized LDL in aortic valve tissue favoring fibrocalcific remodeling of the 
aortic valve, providing additional arguments that support the hypothesis that aortic stenosis is 
a lipid-driven process [43]. Finally, Busseuil et al. have shown that, in rabbits, the infusion of 
an ApoA-1 mimetic peptide leads to the regression of cholesterol-induced aortic valve 
stenosis, suggesting alternative molecular targets for medical treatment of this disease [44].  
Inflammation. From more than a decade it is well known that aortic valve ―early lesions‖ 
are characterized by inflammatory features including T lymphocytes and macrophages [27], 
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but the contribution of inflammation and its mediators has recently become more detailed as 
described by growing evidence. Several inflammation mediators accumulate in diseased 
aortic valves: the terminal complement complex C5b-9 is found in sclerotic and even more in 
stenotic aortic valves [45], that also show increased expression of C3a and C5a receptors [45]; 
in addition, stenotic aortic valves show increased expression of interleuchin-1β and of 
leukocyte infiltrates [46],  of transforming growth factor-β1 (TGF-β1) [47] (and this could 
promote calcification through apoptosis induction of the interstitial aortic cells [48]),  of 
extracellular matrix tumor necrosis factor- α (TNF-α) [49], and of endothelial adhesion 
molecules intercellular adhesion molecule-1 (ICAM-1) [28, 50, 51], of vascular cell adhesion 
molecule-1 (VCAM-1) [28, 51], of  Heat Shock Protein-60 [51], of vascular adhesion protein-
1, eotaxin-3 and of monokine induced by interferon-gamma [47]; such a variety of 
inflammation mediators strongly suggests a sensible contribution of inflammation in the 
course of aortic valve disease. 
Of note is also the fact that normal aortic valves have a substantial expression of the Toll-like 
receptors 2 e 4, which are known to play an important role in pro-inflammatory cytokine 
expression in several cell population, especially in interstitial cells [52]; in vitro studies have 
also shown that Toll-like receptors are fully functional in interstitial aortic valve cells, as 
peptidoglican or lipopolysaccaride stimulation can cause NF-kB pathway activation with 
consequent production and release of proinflammatory cytokines, e.g. interleukin-6 - IL-8 - 
ICAM-1, and of the osteogenesis-related factors bone morphogenetic protein-2 and Runx2 
[52], supporting a causative link between inflammation and osteogenesis in aortic valve 
disease. Such a finding is further supported by  evidence concerning the pathway 
osteoprotegerine/ RANK/RANKL [53, 54] that will be wider discussed in the osteogenesis 
section.  
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Haemostasis. Aortic valve stenosis has been for long time associated with bleeding 
disorders; in 1958 Heyde described the association between frequent gastrointestinal bleeding 
episodes and aortic valve stenosis (Heyde‘s sindrome) [55]; later, it has been reported that the 
bleeding in context of aortic stenosis is due to acquired type 2A von Willebrand disease, 
characterized by a decrease of the large multimers of the von Willebrand factor due to the 
action of ADAMTS-13, a matrix metalloproteinase that acts on von Willebrand factor  
preferentially under conditions of high shear stress (e.g. stenotic aortic valves) [56, 57]. This 
phenomenon leads in some cases to clinically significant bleeding episodes [58, 59], such as 
recurrent gastrointestinal bleedings sometimes associated to angiodysplasia [55, 58, 59]; of 
note, bleeding episodes can sometimes be controlled only by aortic replacement, when von 
Willebrand factor multimers return to normal levels [55, 58-60]. This perturbation of von 
Willebrand factor multimers also affects platelet function with a reduction in platelet count 
[56], prolonged bleeding time [60], impaired shear-induced platelet aggregation [56],  
prolonged closure time at platelet function analyzer [57], and lower P-selectin levels with 
respect to controls [61]. Usually, von Willebrand factor levels and multimers return to normal 
after within six months after surgery [56, 57, 59], with the exclusion of patient-prosthesis 
mismatch [57, 58], although not all studies agree upon this. In fact, Yoshida et al., using 
immunoblotting electrophoresis, have shown a direct linear relation between von Willebrand 
factor antigen and the indexed effective orifice area of the valve prosthesis [59]; on the other 
hand, Goldsmith and coll., using ELISA, have documented an inverse relation between 
plasma von Willebrand factor and the size of the aortic prosthesis [61]. In summary, evidence 
concerning von Willebrand factor behavior before and after surgery for aortic valve disease, 
as well as the differences in the return to baseline in patients with or without patients-
prosthesis mismatch suggest that the abnormalities related to this molecule are not causative 
of aortic valve disease but  much more likely its consequences. 
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Fewer informations are –unfortunately- available about other haemostatic variables; 
preoperative fibrinogen levels are higher in patients candidates to aortic valve replacement 
with respect to controls [61], and this could be due to an increased pro-inflammatory status. In 
addition, patients affected by aortic or mitral disease have a more marked activation of 
coagulation and fibrinolysis, being prothrombin factor F1.2, thrombin-antithrombin complex 
and d-dimer higher than in controls, even if it is actually not known whether aortic and mitral 
valve disease differ somehow in this aspect [62]. Moreover, hypertensive patients who also 
have aortic valve sclerosis features show higher levels of prothrombin factor F1.2 with respect 
to hypertensive patients without aortic valve sclerosis [63]. Finally, experimental evidence on 
experimental animals  suggests that an atherogenic diet (cholesterol-rich or cholesterol-rich 
plus the addition of vitamin D) promotes the development of aortic valve sclerosis together 
with tissue factor expression on the aortic side of the leaflets [64]. 
In summary, current knowledge concerning aortic valve disease and coagulation, fibrinolysis, 
and platelet activation markers suggest that also these pathways can be involved in aortic 
valve disease progression, but additional evidence is necessary to prove these potential 
associations.   
Angiogenesis. Angiogenesis is defined as the outgrowth of new vessels from pre-existing 
blood vessels [65], is regulated by a balance between angiogenic activators such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor-2 and platelet-derived growth 
factor and inhibitors [66], and is one of the main mechanisms involved in atherogenesis 
promoting plaque growth, intraplaque hemorrhage, and lesion instability [67, 68]. Several 
studies have shown that neoangiogenesis occurs in the course of calcific aortic disease, and a 
substantial association with inflammatory infiltrates [30, 51, 69, 70] occurs; interestingly, 
vascular density is higher in aortic valves with a low or intermediate grade of calcification 
and lower or even null in severely stenotic valves [69, 70], suggesting that neoangiogenesis 
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has a specific temporal pattern in the development of this disease. Neovascularization is also 
associated with increased expression of VEGF and  of its receptors Flt-1 e Flk-1, of 
endothelial nitric oxide synthase [69], and of  SPARC (secreted protein, acidic and rich in 
cysteine/osteonectin) [70], an extracellular matrix protein contributing to embryonic 
development, blood vessels formation, and tissue remodeling [71]. Further proof concerning 
angiogenesis role in calcific aortic disease comes also from ex vivo studies showing that new 
capillary sprouts exhibit endothelial markers as  CD31, von Willebrand factor, CD34, and 
tyrosine kinase receptor Tie-2 on their surface. Finally, Chalajour et al. have identified, in 
diseased valves, the presence of a cell population expressing both endothelial (VEGF recptor-
2 and tyrosine chinase receptor Tie-2 expression) and mesenchimal (smooth muscle alpha-
actin expression) markers and with an enhanced angiogenic activity that could promote the 
pathological angiogenesis occurring in stenotic valves via the differentiation of these cells 
into the cell types needed for this process [72]. Taken together, these data suggest that 
angiogenesis is one of the player in the field of calcific aortic stenosis, being a potentially new 
therapeutic target to slow the progression of this disease. 
Extracellular matrix remodeling. Parallel to neovessels formation, diseased aortic 
valves are place of intense remodeling of the extracellular matrix favoring disease 
progression. Several matrix metalloproteases (MMPs), a family of zinc-dependent 
endopeptidases that degrade extracellular matrix [73] are increasingly expressed in stenotic 
aortic valves with respect to controls. In particular, an increase in MMP-1 [46, 49, 74], that 
co-localizes in aortic valves with TNF-α has been observed, which suggests an important link 
between matrix remodeling and inflammation [49]. In addition, other MMPs have been 
assessed in this pathological condition,  as MMP-3 [74, 75], MMP-9 [74-77]. Concerning 
MMP-2, even if some studies have provided evidence for a potential involvement of this 
MMP in the development of aortic valve disease, other have not confirmed this finding [74, 
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76, 78-80]. The behavior of tissue inhibitors of MMPs  1 and 2 (TIMPs) is even more 
controversial: some studies failed to show  TIMPs parallel increases [49] or have shown 
minor increases [77], whereas other have documented sensible increases of these inhibitors 
[75, 80]; it is thus possible that the balance among MMPs and their inhibitors in stenotic 
aortic valves is dependent from cycles or phases of disease progression that are not still well 
characterized, where the prevalence of tissue remodeling may vary over time. In addition, 
other enzymes with  lytic actions on elastic fibers are much more represented in stenotic 
aortic valves than in normal valves: cathepsin G levels are higher in mast cells of patients 
affected by aortic valve stenosis [81];  cathepsins S, K e V are also increased, cathepsin V 
especially in endothelial cells and cathepsin S more in the calcified portions of the valves 
[82]; moreover, the association between cathepsin G and TGF-1β in mast cells further 
supports the main role of inflammation activation in the global process [81]. The inhibition of 
these proteases, as well as the modulation of mast cell activation and of their release of lytic 
substances is a new potential therapeutic target that could help lowering aortic valve disease 
progression [83]; and this is particularly meaningful as it has been recently hypothesized that 
activated mast cells located in the subendothelium of human coronary arteries with parietal 
microthrombi might  contribute to endothelial damage and erosion releasing proteolytic 
substances that damage endothelial cells attachment to subendothelium [84].  
Oxidative stress. It has been documented that, in stenotic aortic valves, oxidative stress is 
increased, as shown by higher levels of superoxide and of hydrogen peroxide compared with 
controls  in  the calcified and peri-calcific regions of the valve [85, 86]. Parallel to the 
increase in reactive oxygen species, there is also a reduction in the expression and activity of 
antioxidant enzymes catalase and of   NADPH oxidase nitric oxide scavenger (Nox) Nox2 
and Nox4 [85]. This is somehow an unexpected finding, as it is well known that upregulation 
of Nox signaling is an important contributor  to atherosclerosis and vascular remodeling [87]. 
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Unlike atherosclerosis, oxidative stress increase occurring in calcific aortic valve disease is 
not due to NADPH oxidase activity rise which, in stenotic valves, is reduced because of 
―NOS uncoupling‖, when molecular oxygen, rather than arginine,  becomes the terminal 
electron recipient with generation of superoxide radicals by nitric oxide synthase [85]. The 
NADPH oxidase downregulation in stenotic aortic valves has not been confirmed, however, 
by others [86], leaving still open the question concerning the mechanisms causing increased 
oxidative stress in aortic valve disease and if these differ or not from the ones active in 
atherosclerosis. 
Infection. The hypothesis that an infective agent, Chlamydia Pneumoniae, was related to 
development and progression of the aortic valve stenosis, has been pursued by several 
Authors over the years, sharing with the infective hypothesis of atheroslcerosis the same 
fortune, a mix of success and failures [88-90]. Both for aortic sclerosis [91] and for  aortic 
valve stenosis [92-96], studies addressing the potential association between Chlamydia and 
calcific aortic disease have not provided definitive answers. About the possible role of other 
infectious agents, Bratos-Perez et al. have recently shown that a significant percentage of 
severely stenotic aortic valves collected at surgery (48/75, 64%), once cultured in appropriate 
media, show the presence of growing self-replicating calcifying nanoparticles, also called 
nanobacteria, that potentially represent new pathogens  under scrutiny, whose presence has 
already been found in carotid disease, abdominal aorta aneurysms, and in calcific human 
vessels or valves [97]. Nevertheless, further evidence is needed for a clear demonstration of 
the role of these agents in calcific aortic disease. 
 
BONE METABOLISM 
 
The role of calcium metabolism in calcific aortic stenosis has been always considered definite 
since for several decades calcific aortic stenosis has been associated with diseases 
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characterized by perturbations in calcium metabolism such as chronic renal failure and 
hemodyalisis [98, 99]. This role  has then been confirmed by several papers demonstrating a 
possible direct association with ionized calcium [100] and an inverse one with total serum 
calcium [101]; in addition, aortic stenosis has been related with higher serum parathormone 
and lower vitamin D  levels in male patients affected by aortic stenosis and coronary disease 
[102]. These data, together with evidence concerning an higher frequency of the B allele of 
Vitamin D in patients with aortic stenosis (see ―Genomics‖ section), confirm the importance 
of systemic calcium metabolism, especially in terms of increased calcium mobilization, in the 
progression of this disease.  
In addition, even if the concept of calcification has been always related to non-rheumatic 
aortic stenosis (which  has been frequently called ―calcific‖) the process underlying 
calcification and, eventually, bone has been attributed for nearly a century to a passive 
degenerative process. 
Only recently, several  studies have documented that calcium deposition and bone formation 
in stenotic aortic valves is an actively regulated process  and that the aortic valve specimens 
collected during aortic valve replacements show heterotopic ossification, active bone 
remodeling and mature lamellar bone [103]; in addition, in these valves there are increased 
levels of several osteoblast markers such as osteopontin [85, 104, 105], osteocalcin [104], 
osteoprotegerin [105], bone  sialoprotein [104, 105], and of the osteoblast-specific 
transcription factor Cbfa1 [85, 104]. Moreover, the endochondral process of bone formation 
leading to aortic valve calcification seems to share several features with mature bone [33], and 
is strictly associated with inflammation [103, 106, 107] and neoangiogenesis [30, 51, 103]; 
besides, the  pathway Lrp5/Wnt, osteoblast differentiation signaling markers that play a 
primary role in bone development [33],  and the osteoprotegerin/RANK (receptor activator of 
nuclear factor-kB/RANKL (the RANK receptor) axis are also involved in aortic valve 
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calcification [53, 54, 108].  RANKL, a member of TNF-α superfamily, is a transmembrane 
protein expressed on osteoblatsts surface, stromal cells, T cells and endothelial cells, that 
interacts with the transmembrane protein RANK on osteoclasts precursors or on mature 
osteoclasts promoting their differentiation via NF-κB. This interaction can be effectively 
blocked by circulating osteoprotegerin that is able to stop osteoclasts differentiation [109, 
110]. Both in aortic sclerosis [54] and in aortic stenosis [53, 54, 111] the relative 
concentrations of the components of this axis are sensibly changed with respect to controls, 
with increases in  RANK e RANKL and a decrease in osteoprotegerin, a pattern promoting 
aortic valve calcification. Current data suggest that the process of aortic valve calcification is 
thus a multifactorial event where several pathways converge to enhance disease progression, a 
complex mechanism that might request a multi-target approach for its modulation. The recent 
demonstration that also adrenergic and purinergic  pathways can contribute to this process, 
confirms and expands the concept of the need of multiple target modulation. Osman et al. 
have in fact shown that  β-adrenergic receptors, especially β2 ones, are upregulated in 
stenotic valves, mainly in peri-calcific areas [111], and the prolonged incubation of cultured 
interstitial aortic valve cells with a stable analogue of the purinergic receptor P2Y (ATP-γ-S) 
causes their differentiation into osteoblasts [112], further supporting a multi-effector and 
multi-cause process.  
 
FLUID MECHANICS 
 
In addition to the role of genomics, atherosclerosis and bone metabolism, fluid mechanics 
perturbations that progressively occur at the site of aortic stenosis may themselves contribute 
to the progression of the disease amplifying the biological changes that underlie the evolution 
of aortic stenosis. As blood velocity increases through a stenotic aortic valve, local 
endothelial shear stress changes and –ultimately- turbulent flow occur. This can activate 
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endothelial cells, tipping the balance of endothelial-derived factors to disrupt barrier function, 
and enhance coagulation, leukocyte adhesion, and smooth muscle cell proliferation [113]. 
Even if these responses likely exist as protective mechanisms, these changes may render these 
responses excessive, resulting in damaged tissue, impaired organ function, and an abnormal 
fibroproliferative response. Besides the previously described effects on hemostatsis via von 
Willebrand factor perturbations, local shear stress changes can affect several different 
pathways related with the progression of aortic stenosis; among them cell cycle, nitric oxide 
and prostacyclin release, oxidative stress, lipoprotein uptake, synthesis and permeability, 
inflammation, vascular muscle cell migration, differentiation and proliferation, and  
neoangiogenesis [114-117]. Finally, it is interesting to note that different shear stress  patterns 
can determine the endothelial and smooth muscle cell phenotype towards activation or 
quiescence [118, 119], further supporting the role of fluid mechanics in aortic stenosis.     
 
Pharmacologic modulation of calcific aortic stenosis progression: basic 
mechanisms and clinical results 
 
From the previous sections it is clear that several mechanisms involved in atherosclerosis are 
also possibly involved in the development and progression of calcific aortic stenosis; the class 
of drugs more widely investigated, on a sperimental ground an in clinical practice, are, as a 
consequence, the HMG-CoA reductase inhibitors, named statins. It is well known that statins 
exert significant anti-inflammatory effects and that they also preserve endothelial function in 
the general population [120, 121], and this concept this might be translated into potential 
beneficial effects for patients affected by aortic valve disease [1, 19, 122], although a 
definitive demonstration of the ―aortic protection‖ is unfortunately still lacking. Atorvastatin 
reduces the progression of aortic valve calcification in rabbits fed with an atherogenic diet via 
Lrp5 pathway [123] and endothelial nitric oxide synthase [124] modulation; in vitro studies 
have also shown that atorvastatin also reduces the activity of alkaline phosphatase, a marker 
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of osteoblast activity, in cultured interstitial aortic cells previously incubated in  osteogenic 
media obtained with the addition of compounds with purinergic activity [112]. Other studies 
have assessed the role  of statin treatment on different cell populations of the aortic valve  
showing that, in animal cell cultures, these drugs exert their maximal effect by limiting the 
formation of calcific nodules and alkaline phosphatase activity of aortic myofibroblasts via 
downregulation of HMG-CoA reductase activity; on the other hand, in  osteoblasts, statins 
favor alkaline phosphatase activity, and they also promote the differentiation in osteoblasts of 
other cell populations such as bone marrow stromal cells [125]. This effect, called ―statin 
paradox‖, suggests the hypothesis that timing of statins administration may be critical in the 
reducing disease progression, as the prevailing cell populations during the various phases of 
the development of aortic stenosis may differ, as well as the response to drug treatment. Other 
potentially beneficial biological effects of statins include the attenuation in the expression of 
pro-inflammatory mediators, although this modulation is incomplete. Indeed, statins reduce 
the expression of the inflammatory markers  eotaxin3, and of a monokine induced by 
interferon-gamma, but not of TGF-β and of vascular adhesion protein-1 [47]. Another proof 
of paradoxical biological effects of statins is the demonstration that these drugs reduce of the 
expression of  regulators of G protein-mediated signaling (RGS) proteins RGS2, RGS3 and  
RGS4 in stenotic aortic valves leading to increase in the activation of extracellular-regulated 
kinases [126] that in turn stimulate further proliferation of myofibroblasts; this suggest that, 
even in this setting, not all the effects of statins are potentially beneficial for prevention of 
stenotic aortic disease progression. This is not totally unexpected, due to the complex 
pleiotropic activities of statins on the overall isoprenoid pathway. Indeed, inhibition of the 
HMG-CoA reductase enzyme by statins, results in the inhibition not only of cholesterol 
biosynthesis, but it influences the generation of a variety of isoprenoid compounds, important 
in cell cycle, inflammation and osteogenesis, as well.  
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Concerning clinical studies, both retrospective and prospective studies have addressed the 
question whether statin therapy can reduce the progression of this disease, reaching 
controversial results, as the majority of retrospective studies document a protective effect of 
statins on aortic valve stenosis evolution, whereas the majority of prospective and all 
prospective and randomized  trials do not. The prospective randomized SALTIRE has 
enrolled patients affected by aortic stenosis with total cholesterol levels ≥ 150 mg/dL and with 
a jet velocity ≥ 2.5 m/sec; overall, patients average jet velocity was 3.42 m/sec, with a peak 
gradient of 48 mmHg, and an aortic valve area of 1.03 cm
2
.  The results of  SALTIRE show 
that a high-dose (80 mg/die) of atorvastatin therapy fails to show any effect,  at a median 
follow-up of 25 months, on the primary end-points of the study, assessing aortic stenosis 
progression. The echocardiographic annual change in jet velocity was  0.199 m/s in 
atorvastatin-treated patients, and 0.203 m/s in placebo-treated (p=0.95), whereas the valve 
calcium score increase, assessed with helical computed tomography, was  22.3% and 21.7% 
in statin and placebo group, respectively (p=0.93) [127]. Unlike SALTIRE trial, the RAAVE 
trial, a prospective open-label study assessing the effect of rosuvastatin treatment on aortic 
stenosis over 18 months, has documented significant improvements in aortic stenosis 
progression in  statin-treated patients. With respect to SALTIRE, patients enrolled in RAAVE 
had higher aortic valve areas (1.23 cm
2
) but similar jet velocities (3.63 m/s) at baseline; in this 
latter study, treatment was not assigned by randomization, but patients presenting with 
abnormally high LDL cholesterol levels (> 130 mg/dL) received rosuvastatin, whereas 
patients with lower LDL levels received no statin. RAAVE has shown that aortic valve area 
decreased annually in both groups, but statin-treated patients had half the progression with 
respect to untreated patients (decrease in aortic valve area 0.05 vs. 0.1 cm
2
 per year, p=0.04) 
[128].  
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Recently, results of the prospective randomized study SEAS, the biggest one up to date in this 
field, have been published; in this study 1873 patients with LDL values < 236 mg/dL, with an 
average aortic valve area of  1.28 cm
2
 and an average jet velocity of  3.1 m/s, were enrolled; 
these patients have been randomized to be treated for a minimum of four years with placebo 
or ezetimibe/simvastatin, for a median follow-up of 52.2 months. In SEAS, 
ezetimibe/simvastatin was no better than placebo in reducing the primary composite end point 
of aortic valve-related and cardiovascular events (defined as death from cardiovascular 
causes, aortic-valve replacement,  congestive heart failure as a result of progression of aortic-
valve stenosis, nonfatal myocardial infarction, hospitalization for unstable angina, coronary-
artery bypass grafting, percutaneous coronary intervention, or non-hemorrhagic stroke), 
occurring similarly in  treated patients (35.3%) and in controls (38.2%, p=0.59). In addition, 
the secondary end-point of aortic valve-related  events (defined as aortic-valve replacement 
surgery, congestive heart failure due to aortic stenosis, or death from cardiovascular causes) 
did not differ between groups, occurring in 32.6% and 35.1%  of cases and of controls, 
respectively (p=0.73). On the other hand,  this treatment  was significantly more effective 
than placebo in reducing the risk of ischemic events, a secondary composite end point driven 
primarily by reductions in coronary artery bypass graft surgery; this occurred in 15.7% and  
20.1% of cases and of controls, respectively (p=0.02) [129]. In addition, this study has raised 
some concerns over the significantly increased risk of cancer of treated patients being doubled 
in patients who received ezetimibe/simvastatin. The new cancers, however, were not specific 
to one site, and an interim analysis of ongoing ezetimibe/simvastatin studies SHARP and 
IMPROVE-IT, plus the analysis from SEAS,  revealed no increased risk [130] 
Finally, the results of  another randomized trial, ASTRONOMER, are expected for the end of 
this year; this study will address the effect of rosuvastatin (40 mg/d) treatment on aortic valve 
stenosis progression  in patients in 272 patients with an average jet velocity of 3.2 m/s,  an 
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aortic valve area of 1.2 cm
2
, a mean transvalvular gradient of 22 mmHg, half of them having 
bicuspid aortic valve, for a 3 to 5 years follow-up period [131]. In addition, other prospective 
randomized studies concerning statins and aortic valve disease are currently running, and the 
results of a search of these trials on the site www.clinicaltrials.gov, performed on 
26/08/2008), is reported in Table 1. 
As stated before, evidence from retrospective nonrandomized studies is in contrast with what 
has been previously shown by randomized ones. Although publication bias in this case can 
not totally be excluded, data from these studies consistently show that statin therapy reduces 
the progression of aortic valve disease, whatever the degree of stenosis was documented at the 
beginning of follow-up, and this result has been documented both with echocardiography 
[132-135] or with CT scan for detection of calcium content of the aortic valve  [40, 136, 137].  
Based on these data, we can infer that statins are a class of drugs with potentially beneficial 
effect on the reduction of valve disease progression, but this is not demonstrated yet; it is also 
possible, in our opinion, that timing is the most critical factor for the optimal efficacy of this 
class of drugs, and that their maximal effects are obtainable at earlier stages of the disease 
such as aortic sclerosis. In support of this hypothesis, a recent retrospective study of Antonini-
Canterin analyzing 1046 patients over 19 years has shown that, at an average follow-up of 5.6 
± 3.2 years,  statins can reduce aortic stenosis progression only in the milder degrees of the 
disease, such as in case of aortic sclerosis (jet velocity ≥ 1.5 and < 2.0 m/s) or in case of 
moderate aortic stenosis (jet velocity ≥ 2 and < 3 m/s). When aortic stenosis was more severe 
(jet velocity ≥ 3 and < 4 m/s), the effect of statins was null [138]. If this will be confirmed by 
appropriate studies, it may strongly impact prevention programs of health systems which will 
have to consider to screen for and to treat  aortic sclerosis. It should be noted, however, that 
all the randomized trials done up to date or still running might have unfortunately missed the 
patient population where statins are more effective, as all studies have enrolled patients with 
36 
 
jet velocities almost always > 3.0 m/s, and therefore might fail to provide evidence of the 
potential benefits of statins in the relatively early phases of abortive valve disease, namely 
during the phase of aortic sclerosis. Finally, it is well known that the progression of sclerosis 
and stenosis and especially of sclerosis toward stenosis is substantially unpredictable in the 
individual patient, being  in some cases very slow, in others quite accelerated, and that 
different patterns of aortic valve disease progression (linear and non-linear) are possible 
[139]; this, together with evidence concerning the potential beneficial effects of statins in 
aortic valve sclerosis and not in aortic valve stenosis, suggests that the assumption that valve 
sclerosis is always and invariably the precursor of valve stenosis may not be completely 
correct.  
Converting enzyme inhibitors are another  class of drugs with potentially beneficial effects on 
aortic stenosis progression as the presence of converting enzyme has been shown both in 
sclerotic [18, 32] and stenotic aortic valves [32, 140], as well as chimase [140]; both these 
enzymes are involved in Angiotensin II production, a molecule with proinflammatory and 
profibrotic activity; but clinical data, although scarce, actually do not show any effect of these 
drugs on this disease  [135].  
Moreover, preliminary evidence from animal models suggest that olmesartan, an angiotensin 
type 1 receptor antagonist,  reduces atherosclerotic changes in aortic valves by preserving 
endothelial cells integrity and inhibiting transdifferentiation into myofibroblasts or into 
osteoblasts in valve leaflets [141], but no clinical data about this class of drugs is still actually 
available. 
Finally, another potential therapeutic target to reduce aortic stenosis progression is smoke 
cessation. It has been shown that nicotine and acetaldehyde, both smoke components, induce 
TGF-β1 expression in cultured fibroblasts, and nicotine can also activate mast cells; both 
these mechanisms can ultimately lead to an increased collagen/elastin ratio in valve tissue 
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[81]; this finding suggests a potential role also for smoke cessation in the prevention of 
calcific aortic disease.  
 
CONCLUSIONS 
 
The progression of calcific aortic stenosis is a multi-factorial process resembling the 
atherosclerotic process, with nevertheless some important  differences in the final results 
achieved, since in atherosclerosis the final result is plaque development and plaque instability 
whereas calcific aortic disease ends up in severe calcification of the aortic valve. This 
suggests that calcific aortic stenosis is not a single disease process but it seems to be more 
likely a common macroscopic anatomic equivalent of a series of partly related  processes that 
ultimately lead to severe calcification of the valve.  
The multitude of the mechanisms potentially involved in aortic disease progression, together 
with the available clinical evidence strongly suggests that drug therapy aimed at reducing this 
progression will have necessarily to be multi-factorial and will have to address the earliest 
stages of the disease, as it is now clear that drug therapy administered in more advanced 
stages of the disease may be ineffective or, at best, much less effective. The time has come to 
integrate all the possible mechanisms affecting the development and progression of aortic 
stenosis into a unique effort to discover innovative therapies that may lead to lower evolution 
over time. 
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Table 1 
Ongoing studies available on clinicaltrials.gov (26/08/2008) concerning aortic valve stenosis and statin therapy 
 
Study Institution  (Principal 
investigator), patients 
Treatment Duration of 
follow-up 
Primary end-point  Secondary end-point Expected 
termination 
AORTICA AORTICA GROUP 
(Pedro L Sanchez); 
164 patients with  jet 
velocity > 2 m/sec 
Placebo, Fluvastatin 
(80 mg) 
12 months Changes in C-reactive protein 
concentration at  the end of 
treatment 
Changes in inflammatory 
markers, in valve area, and in 
transvalvular gradients at the 
end of treatment 
November 
2008 
ROCK-AS Helsinki Univ. 
(Markku Kupari); 120 
patients candiudates to 
surgery 
Placebo, Rosuvastatin 
(20 mg), Candesartan 
(16 mg), Candesartan 
+Rosuvastatin 
3-5 months Inflammation degree in stenotic 
aortic valves explanted during 
the intervention 
Calcification, lipid accumu-
lation and fibrosis degree  in 
stenotic aortic valves 
explanted during the 
intervention 
December 
2013 
STAAT Leipzig Univ. 
(Claudia Walther); 
100 patients with 1.5 
> aortic valve area 
>0.8 cm2 
Placebo, Fluvastatin 
(20-40 mg)  
24 months Aortic valve stenosis 
progression assessed as valve 
area, peak and mean 
transvalvular gradients at 
echocardiogram, and as peak-to-
peak gradient at catheterization 
Not available December 
2008 
STOP-AS Cleveland Clinic 
(Brian P Griffin); 70 
patients with  1.7 > 
aortic valve area >0.9 
cm2 
Atorvastatin (40 mg) 
(vs internal controls 
and vs historical 
controls) 
24 months Rate of change in the aortic 
valve area as measured by 
transthoracic echocardiography 
Rate of change in the aortic 
valve area measured by 
transthoracic echocardiogra-
phy compared to that of 
historical controls, to standard 
of care group, and  change in 
the mean and peak gradients 
across the aortic valve as 
measured by transthoracic 
echocardiography in the 
treated group compared to 
historical control group 
June 2008 
(not yet 
published) 
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2.4  Do statins improve outcomes and delay the progression of 
non-rheumatic calcific aortic stenosis?  
 
INTRODUCTION 
 
Non-rheumatic calcific aortic stenosis is the commonest valve disease in adults and the third 
most common cardiovascular diagnosis (after hypertension and need for coronary bypass 
surgery).[1] Surgery remains the only treatment option in advanced stages.[1] As several 
studies have indicated that aortic stenosis progression is due to an active process sharing 
several features with atherosclerosis, several trials have assessed the role of statins in delaying 
such progression, but with conflicting results.[2, 3] Since 2001, several studies, mainly 
observational, suggested that statin therapy delays the progression of calcific non-rheumatic 
aortic stenosis, assessed by echocardiography or computed tomography. These findings were 
not confirmed by three recent prospective randomized trials.[4, 5, 6] For this reason, the role 
of statins in these patients is an open question. We have undertaken a meta-analysis of studies 
of the effect of statins on the incidence of hard end-points and on retarding stenosis 
progression. 
 
METHODS 
 
The meta-analysis used PRISMA,[7]  and MOOSE guidelines.[8]  We performed a 
computerized literature search of Medline and PubMed up to  January 2010, supplemented 
with manual bibliography reviews. The following free text search string (formatted for 
PubMed) was used: [(statins OR Hydroxymethylglutaryl coenzyme-a reductase inhibitors) 
AND aortic]. We used tangential electronic exploration of related articles and manual 
searches of bibliographies, related journals, and reference lists of reviews. All peer-reviewed 
studies published  reporting the effect of statin therapy on outcomes and on valve stenosis 
progression in patients with calcific non-rheumatic aortic stenosis were identified. The ability 
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of the search strategy to identify four relevant studies was tested and found fit for purpose. All 
titles and abstracts of the identified articles were examined by two investigators (AP, DP) for 
potential eligibility for subsequent analysis.  
The first step of the analysis was to collect all the trials conforming to the following criteria: 
1. Studies comparing the mid- or long-term effects (≥ 1 year) of statin therapy vs. 
placebo or no statins in patients affected by calcific non-rheumatic aortic stenosis; 
2. Data concerning mid- or long-term hard outcomes or about the progression of aortic 
stenosis had to be reported in the study.  
The following hard endpoints were collected: 
1. Death from any cause at follow-up (n/y); 
2. Death from cardiovascular causes at follow-up (n/y); 
3. Need to undergo aortic valve surgery at follow-up (n/y). 
Concerning aortic valve stenosis progression, the following variables were searched: 
1. Peak aortic-jet velocity progression (m/s/y); 
2. Aortic valve area decrease (cm2/y); 
3. Peak aortic gradient progression (mmHg/y); 
4. Mean aortic gradient progression (mmHg/y); 
The outcome definitions used by the original researchers were accepted. Bibliographies of 
included articles were also searched.  
Several strategies were employed to avoid duplication of data. If the same institution had 
produced several studies, only those reporting recruitment times were considered. If there was 
sample overlap between studies, only the largest study was included. Data were abstracted 
and analyzed by two authors (AP, MT), and disagreements were resolved by consensus.  
Analyses. Data were analyzed by means of RevMan 5 (RevMan 5.0.22, Cochrane 
Collaboration, Oxford, United Kingdom) and Comprehensive Meta-analysis Version 2 
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(Biostat, Englewood, NJ). Effects on dichotomous outcomes were expressed as odds ratio 
(OR) with 95% confidence intervals (CI). Effects on continuous variables were expressed as 
mean difference with 95% CI. 
Heterogeneity was assessed with the Chi
2
  test; in addition, the I
2
 was calculated to quantify 
the degree of heterogeneity across trials that could not be attributable to chance alone. I
2
, the 
proportion of variability not attributable to chance alone, provides an improved measure of 
heterogeneity between trials and is not limited by power.[9] When there was no significant 
heterogeneity, treatment effects were pooled with the fixed-effects model, but if there was 
significant (p≤0.1) heterogeneity in the main analysis or in a subanalysis, the random-effects 
model was used; when a random-effects analysis was performed, among-study variance was 
also assessed with Tau
2
 statistic.  
Subanalyses, defined a priori, were the analyses of prospective and retrospective studies, and 
of randomized and nonrandomized studies done separately. In addition, the effect of statin 
treatment on aortic stenosis progression parameters was assessed in studies that enrolled 
patients with average LDL cholesterol levels ≤ 130 mg/dL.  Finally, weighted fixed-effects 
meta-regression was used to examine the possibility of effect modification on aortic stenosis 
progression by duration of statin treatment.    
Sensitivity of the meta-analyses was assessed after removal of studies in which the largest (or 
smallest) effect was found and of  the study with the largest number of patients. In addition, 
we performed random-effects meta-analysis on the outcomes of interest. 
Publication bias was explored through visual inspection of funnel
 
plots, and by one-tailed 
Egger‘s test. Other than for the Q statistic, statistical significance was defined by p ≤ 0.05. 
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RESULTS 
 
Selected studies 
The selection criteria described under Methods were applied to 812 studies identified by the 
literature searches, the publications were examined, and 21 candidate trials were identified for 
further assessment (see online supplementary data for bibliography). Of these, 6 were 
discarded as they were not focused on therapy with statins. On further examination of these 
15 remaining studies, 5 were excluded either because they did not report any extractable data, 
because of possible duplicate publication, or because they were focused on rheumatic aortic 
stenosis. Of the 10 studies finally selected for meta-analysis (Table 1), 5 were prospective, 5 
retrospective,  whereas 3 were randomized, and 7 not randomized, respectively. One of the 
retrospective, non-randomized studies[10] reported separately the outcomes for patients 
affected by mild aortic stenosis and moderate aortic stenosis, and for that reason data 
concerning these subcategories of patients were inserted separately into the meta-analysis. 
In the end, a total of 3822 participants (2214 non statin-treated and 1608 statin-treated) in 10 
studies provided data for this meta-analysis.  
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Table 1 
Characteristics of included trials 
 
Study Year Study design Treatment groups 
No. of 
pts. 
Age (y) 
LDL 
cholesterol 
(mg/dL) 
Diabetes 
Aortic jet 
velocity 
(m/sec) 
Aortic valve 
area (cm
2
) 
Transaortic 
pressure 
gradient 
(mmHg) 
Follow-up 
Chan 
(ASTRONOMER) 
[6] 
2010 
Prospective 
randomized 
Placebo 
Rosuvastatin 40 mg/d 
135 
134 
58±14 
58±13 
122±29 
124±25 
n.a. 
n.a. 
3.19±0.42 
3.16±0.42 
1.56±0.70 
1.49±0.71 
Mean:23±8 
Mean:23±8 
Median 3.5  
(2.1-4.5) years 
            
Cowell  
(SALTIRE) [4] 
2005 
Prospective 
randomized 
Placebo 78 68±10 133±30 4 (5%) 3.45±0.67 1.02±0.41 Peak:50±20 Median: 25  
(7-36) months Atorvastatin 80 mg/d 77 68±10 137±34 3 (4%) 3.39±0.62 1.03±0.40 Peak:48±17 
            
Mohler [11] 2007 
Prospective 
observational 
No statins 
Statins 
22 
31 
64±10 
70±10 
}110±33 3 (14%) 
7 (18%) 
n.a. 
n.a. 
1.22±0.25 
1.13±0.27 
n.a. 
n.a. 
12 months 
            
Moura  
(RAAVE) [12] 
2007 
Prospective 
open label 
No treatment 60 74±9 117±21 13 (22%) 3.62±0.61 1.20±0.35 Mean:36±13 Mean: 73±24 
weeks Rosuvastatin 20 mg/d 61 73±9 158±32 26 (43%) 3.65±0.64 1.23±0.43 Mean:35±13 
            
Rossebo  
(SEAS) [5] 
2008 
Prospective 
randomized 
Placebo 929 67±10 139±35 n.a. 3.10±0.54 1.27±0.46 Mean:23.0±8.7 
Median: 52.2 
months 
Simvastatin (40-80 
mg/d) plus ezetimibe 
944 68±9 140±36 n.a. 3.09±0.55 1.29±0.48 Mean:22.7±8.8 
            
Antonini-Canterin 
[10] 
2008 Retrospective 
No statins: mild 
aortic stenosis 
360 71±8 n.a. 82 (23%) 2.3±0.2 n.a. Mean:13.1±3.2 
Mean: 5.6±3.2 
years 
Statins: mild aortic 
stenosis 
141 71±7 n.a. 50 (36%) 2.3±0.2 n.a. Mean:12.7±3.1 
No statins: moderate 
aortic stenosis 
214 72±8 n.a. 42 (20%) 3.3±0.2 n.a. Mean:26.1±5.1 
Statins: moderate 
aortic stenosis 
62 70±8 n.a. 14 (23%) 3.3±0.2 n.a. Mean:26.0±5.0 
            
Bellamy [13] 2002 Retrospective 
No statins 118 78±12 137±43 28 (24%) 3.0±0.8 1.20±0.35 Mean:22±12 Mean: 3.7±2.3 
years Statins 38 73±11 164±49 9 (24%) 2.8±0.5 1.32±0.29 Mean:18±7 
Kuwabara [14] 2006 Retrospective 
No statins  
Statins 
20 
13 
75±5 
74±5 
n.a.  
n.a. 
3 (15%) 
6 (46%) 
}3.1±1.0 n.a 
n.a. 
}Mean:42±29 31±23 months 
30±20 months 
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Novaro [15] 2001 Retrospective 
No statins 117 67±13 131(112-143) 23 (20%) n.a. 1.2(1.0-1.4) Mean:15(12-22) 
Mean:21 months 
Statins 57 71±9 128(94-146)  20 (35%) n.a. 1.2(1.0-1.4) Mean:15(12-22) 
            
Rosenhek [16] 2004 Retrospective 
No statins 161 69±11 141±39 32 (20%) 3.92±0.86 0.84±0.23 Mean:42±20 Median: 24±18 
months Statins 50 72±8 145±38 11 (22%) 4.08±0.86 0.82±0.23 Mean:42±18 
 
Footnote to Table 1: pts.= patients; n.a.= not available 
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Meta-analysis 
 
As to outcomes, there were no differences between statin-treated and untreated patients. All-
cause mortality (OR 0.98; 95% CI 0.74, 1.30, figure 2 panel A), cardiovascular mortality (OR 
0.79; 95% CI 0.54, 1.15, figure 2 panel B), and the need for aortic valve surgery (OR 0.92; 
95% CI 0.76, 1.10, figure 2 panel C) were not statistically significantly reduced. Notably, data 
concerning hard outcomes were available only in prospective but not in retrospective trials. 
Concerning the progression of aortic valve stenosis over time (Tables 2 and 3), the  analysis 
of the variables (jet velocity progression, mean annual decrease in aortic valve area, peak and 
mean aortic gradient progression)  that were considered  gave consistent results showing that 
a possible protective effect of statins is supported only by low quality studies (retrospective or 
non-randomized), but not by high quality-ones (prospective and randomized).  
In fact, although the overall effect of  statin treatment on the mean annual difference of jet 
velocity progression (-0.08 m/s/y,  95% CI -0.13, -0.03, p=0.0007, figure 3 panel A) and the 
mean annual difference in aortic valve area, (-0.02 cm
2
/y, 95% CI -0.03, 0.00, p=0.02, figure 
3 panel B) was statistically significant, the subanalyses based on the quality of studies showed 
that the effect was driven only by lower quality studies whereas in higher quality ones there 
was no effect. The progression of peak aortic gradient (-1.76 mmHg/y, 95%CI -3.73, 0.21; 
p=0.08, figure 4 panel A) and mean aortic gradient (-0.99 mmHg/y, 95%CI -2.04, 0.07, 
p=0.07 figure 4 panel B) was slightly lower in statin-treated patients, but this did not reach 
statistical significance; also in this case the discrepancy in statin effect  between high- and 
low-quality studies was evident, being only lower quality studies in favor of statin treatment. 
Finally, there was heterogeneity in the analyses concerning the progression of  jet velocity, of 
peak and mean aortic gradient; and  the inspection of funnel plots in these cases showed 
asymmetry suggesting publication bias (the funnel plots are available from the author upon 
request) with a significant Egger‘s test (Tables 2 and 3). 
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Concerning the analysis of statins effect on aortic stenosis progression parameters in studies 
that enrolled patients with average LDL cholesterol levels ≤ 130 mg/dL, only three out of ten 
studies were available for final analysis, and data were available for aortic valve area decrease 
over time, and for peak and mean aortic gradient progression, but not for jet velocity 
progression. Statin treatment did not affect these parameters (please see supplementary data 
eFigure2, panels A-C), but the limits due to a small sample size should be considered. Finally, 
meta-regression analyses did not support a role of statin treatment duration in  aortic stenosis 
progression. 
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Table 2 
Clinical outcomes by prospective and retrospective studies 
 
Hard outcomes n (N) 
Events 
OR 
(95% CI) 
p for overall effect 
Heterogeneity 
Egger’s test 
p value Statins No statins 
p value 
(Q statistic) 
I
2
 
Death from any cause (only                                                        
prospective studies available) 
2149 (3) 109/1082 (10.1%) 109/1067 (10.2%) 0.98 (0.74, 1.30) 0.91 0.33 9% 
0.15 
Death from cardiovascular  
causes (only prospective studies 
available) 
2297 (3) 52/1155 (4.5%) 64/1142 (5.6 %) 0.79 (0.54, 1.15) 0.22 0.67 0% 0.70 
Aortic valve surgery (only 
prospective studies available) 
2418 (4) 311/1216 (25.6%) 327/1202 (27.2%) 0.92 (0.76, 1.10) 0.35 0.43 0% 
0.99 
 
Aortic valve stenosis progression  n (N) Mean difference (95% CI) p for overall effect 
Heterogeneity 
Egger’s test 
p value p value 
(Q statistic) 
I
2
 
Jet velocity  progression (m/s/y) 
    Prospective studies 
    Retrospective studies 
3125 (7) 
1948 (3) 
1177 (4) 
-0.08 (-0.13, -0.03) 
-0.05 (-0.13, 0.03) 
-0.11 (-0.17, -0.04) 
0.0007 
0.22 
0.002 
<0.00001 
0.01 
0.0002 
82% 
78% 
82% 
0.02 
       
Aortic valve area decrease (sq cm/y) 
    Prospective studies 
    Retrospective studies 
2608 (7) 
2278 (5) 
330 (2) 
-0.02 (-0.03, 0.00) 
-0.01 (-0.03, 0.00) 
-0.05 (-0.09, -0.01) 
0.02 
0.15 
0.01 
0.24 
0.29 
1.00 
25% 
19% 
0% 
0.21 
       
Peak aortic gradient progression (mm Hg/y) 
    Prospective studies 
    Retrospective studies 
731 (5) 
524 (3) 
207 (2) 
-1.76 (-3.73, 0.21) 
-0.67 (-2.89, 1.54)  
-3.08 (-5.22, -0.94) 
0.08 
0.55 
0.005 
0.05 
0.15 
0.34 
57% 
47% 
0% 
0.03 
       
Mean aortic gradient progression (mm Hg/y) 
    Prospective studies 
    Retrospective studies 
2413 (5) 
2083 (3) 
330 (2) 
-0.99 (-2.04, 0.07) 
-0.36 (-1.25, 0.53)  
-1.92 (-3.55, -0.29) 
0.07 
0.43 
0.02 
0.008 
0.12 
0.22 
71% 
53% 
35% 
0.04 
 
Footnote to Table 2: n = number of patients; N = number of trials; OR = odds ratio; CI = confidence interval 
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Table 3 
Clinical outcomes by randomized and nonrandomized studies 
Hard outcomes n (N) 
Events 
OR 
(95% CI) 
p for overall effect 
Heterogeneity 
Egger’s test 
p value Statins No statins 
p value 
(Q statistic) 
I
2
 
Death from any cause 
    Randomized studies 
    Non-randomized studies 
2149 (3) 
2028 (2) 
121 (1) 
109/1082 (10.1%) 
108/1021 (10.6%) 
1/61 (1.6%) 
109/1067 (10.2%) 
105/1007 (10.4%) 
4/60 (6.7%) 
0.98 (0.74, 1.30) 
1.01 (0.76, 1.35) 
0.23 (0.03, 2.15) 
0.91 
0.92 
0.20 
0.33 
0.46 
n.a. 
9% 
0% 
n.a. 
0.15 
         
Death from cardiovascular  
causes (only randomized studies 
available) 
2297 (3) 52/1155 (4.5%) 64/1142 (5.6 %) 0.79 (0.54, 1.15) 0.22 0.67 0% 0.70 
         
Aortic valve surgery 
    Randomized studies 
    Non-randomized studies 
2418 (4) 
2297 (3) 
121 (1) 
311/1216 (25.6%) 
306/1155 (26.5%) 
5/61 (8.2%) 
327/1202 (27.2%) 
324/1142 (28.4%) 
3/60 (5.0%) 
0.92 (0.76, 1.10) 
0.91 (0.76, 1.09)  
1.70 (0.39, 7.44) 
0.35 
0.30 
0.48 
0.43 
0.35 
n.a. 
0% 
4% 
n.a. 
0.99 
 
Aortic valve stenosis progression  n (N) Mean difference (95% CI) p for overall effect 
Heterogeneity 
Egger’s test 
p value p value 
(Q statistic) 
I
2
 
Jet velocity  progression (m/s/y) 
    Randomized studies 
    Non-randomized studies 
3125 (7) 
1827 (2) 
1298(5) 
-0.08 (-0.13, -0.03) 
-0.01 (-0.03, 0.02) 
-0.12 (-0.18, -0.06) 
0.0007 
0.48 
0.0002 
<0.00001 
0.88 
<0.0001 
82% 
0% 
81% 
0.02 
       
Aortic valve area decrease (sq cm/y) 
    Randomized studies 
    Non-randomized studies 
2608 (7) 
2096 (3) 
512 (4) 
-0.02 (-0.03, 0.00) 
0.00 (-0.02, 0.02) 
-0.05 (-0.07, -0.02) 
0.02 
0.75 
0.0004 
0.24 
0.93 
0.90 
25% 
0% 
0% 
0.21 
       
Peak aortic gradient progression (mm Hg/y) 
    Randomized studies 
    Non-randomized studies 
731 (5) 
403 (2) 
328 (3) 
-1.76 (-3.73, 0.21) 
0.10 (-1.36, 1.56) 
 -3.40 (-5.39, -1.41) 
0.08 
0.89 
0.0008 
0.05 
0.86 
0.46 
57% 
0% 
0% 
0.03 
       
Mean aortic gradient progression (mm Hg/y) 
    Randomized studies 
    Non-randomized studies 
2413 (5) 
1962 (2) 
451 (3) 
-0.99 (-2.04, 0.07) 
-0.10 (-0.36, 0.16) 
-2.19 (-3.35, -1.03) 
0.07 
0.46 
0.0002 
0.008 
1.00 
0.38 
71% 
0% 
0% 
0.04 
Footnote to eTable  1: n = number of patients; N = number of trials; OR = odds ratio; CI = confidence interval
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DISCUSSION 
 
Non-rheumatic calcific aortic stenosis is the leading valve disease of  Western countries and is 
closely related to aging. Less invasive techniques for valve replacement (i.e. transcatheter 
aortic valve implantation) have recently been introduced in clinical practice,[17] and these 
techniques will allow further growth in aortic valve surgical procedures in a wider population 
of older patients. This, however, will cause an increase in health expenditure for this disease 
that now is estimated to be around 1 billion US dollars per year in the USA.[18] Thus, the 
possibility of reducing the progression of this disease with drug therapy is consequently of 
great interest for all health organizations.  
The assumption that calcific aortic stenosis is only a passive, age-related disease has been 
strongly questioned by numerous studies showing that this disease has several biological 
pathways in common with atherosclerosis, [3]  which is why investigators have assessed the 
effect of statins in this type of patients. 
Statins reduce the occurrence of ischemic cardiovascular events not only in secondary 
prevention but also in high-risk otherwise healthy patients who are candidates for primary 
prevention.[19] In addition, evidence from the JUPITER trial suggests that statin treatment in 
patients with normal cholesterol levels but elevated C-reactive protein reduces the risk of 
cardiovascular disease mortality and morbidity by almost half,[20] showing that, besides their 
cholesterol-lowering effects, statins possess pronounced anti-inflammatory and anticoagulant 
effects.[21, 22] Statins might therefore modulate the progression of non-rheumatic calcific 
aortic stenosis in three ways: by reducing cholesterol levels, a well-known risk factor for 
aortic stenosis;[3] by attenuating the inflammatory burst within valve tissue;[3] and by 
modulating systemic,[3] and local [23] hemostatic changes involved in the course of the 
disease. 
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Studies investigating the clinical results of statin treatment have given contradictory results. 
The early enthusiastic findings of observational studies documenting a reduction of  the 
progression of the disorder have been seriously questioned by later, randomized studies, 
which showed substantial equivalence between statin- and placebo-treated patients.   
The meta-analysis reported here shows that, on the basis of data published to date, statin 
treatment: 1) does not affect the occurrence, at a mid-term follow-up (average 4 years), of 
major events in patients affected by calcific non-rheumatic aortic stenosis; 2) might  reduce 
the rate of aortic stenosis progression over time, but current evidence  is not sufficient at all to 
warrant statin use in these patients, as it comes only from retrospective, nonrandomized 
studies, whereas prospective and randomized studies do not show any proptective effects of 
statins on aortic stenosis progression. 
Thus, although statins have well-established effects on major end-points in several patient 
populations, both in primary and secondary prevention, they do not have the same effect on 
major end points in patients with calcific aortic stenosis. In fact, our meta-analysis of current 
evidence shows that statins do not reduce total mortality, cardiovascular mortality or the need 
for valve surgery after 24-48 months of treatment in this cohort of patients. However, the 
number of patients that could be pooled in this analysis was rather small, and multicenter, 
prospective, randomized studies are needed to clarify the issue definitively. We estimate that a 
sample size of  6220 and of 11150 patients for each treatment arm would be needed to 
demonstrate statistically significant differences between treatments in cardiovascular 
mortality and need for aortic valve surgery, respectively, at mid-term (mean 39 months) 
follow-up (alpha 0.05, power=0.80).  
In the patients in our meta-analysis, the effect of statin treatment on hard outcomes was 
distinctly inferior to that obtained in the JUPITER trial, where the incidence of major 
outcomes was halved by statin therapy in patients with normal cholesterol but with elevated 
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inflammatory markers. We hypothesize that statins are most effective during the early stages 
of stenosis, when inflammation is most active, whereas in the patients we studied the degree 
of stenosis was far  more advanced, as shown by an average jet velocity in all studies > 3 
m/sec and by an average aortic valve area between 1 and 1.4 cm
2
 (Table 1). And this  
hypothesis is also supported by a recent post-hoc analysis of SEAS trial data documenting 
that in patients affected by calcific aortic stenosis the protection provided by statin treatment 
is greater in patients with milder aortic stenosis degrees.[24]  
Against the hypothesis of inflammation contribution to aortic stenosis progression is the 
finding that C-reactive protein has been localized in valve tissue of calcific aortic stenosis and 
that statin-treated patients show lower valve levels of this marker.[25] However, there is some 
doubt whether there is an association between C-reactive protein and disease 
progression.[26],[27] 
Our meta-analysis also shows that statin treatment might have, if any, a little role in reducing 
the progression of aortic stenosis over time, with an annual estimated reduction of  0.08 m/s/y 
for peak jet velocity, and an annual reduction of 0.02 cm
2
/y for aortic valve area decrease. 
Otto et al.[28] showed that, in asymptomatic patients affected by calcific aortic stenosis 
(average valve area of 1.3 cm
2 
and average aortic jet velocity of 3.6 m/s), the approximate 
annual increase in jet velocity is 0.3 m/s
 
with a corresponding decrease of about 0.1 cm
2
 in 
valve area. Based on these data,  statin treatment in the patient population of our meta-
analysis might reduce aortic stenosis progression by an estimated 20%-25%. This finding, 
however, is not confirmed by the behavior of peak and mean aortic gradient; the progression 
of both these variables was slightly affected by statins, but this was not statistically 
significant.  
In addition, the subanalyses performed on data coming from prospective vs. retrospective 
studies, and from randomized vs. non-randomized trials, constantly showed that, for all the 
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four variables representing aortic stenosis progression, the effect of statin treatment was 
evident only in the studies of lower quality (retrospective and non-randomized), whereas no 
effect was demonstrated in high-quality ones (prospective or randomized).  
We conclude that a beneficial effect of statins on disease progression is supported only by 
observational studies, with all their inherent flaws, and this is not sufficient to support statin 
use in patients affected by moderate or by higher grades of  nonrheumatic calcific aortic 
stenosis. Future randomized studies will need to address three deficiencies in those currently 
available: (1) lack of statistical power in detecting any reduction in cardiovascular mortality; 
(2) too short follow-up periods, given that the disease process takes many decades 
 
and only 
about 9% of patients in patients aged 65-75 years with aortic sclerosis progress to aortic 
stenosis in 5 years;[29] and (3) insufficient discrimination in the selection of patients most 
likely to benefit from preventive statin therapy. It has been previously hypothesized that, in 
studies conducted up till now, statin therapy was initiated much too late in the course of 
disease, and that statin therapy should be initiated at an earlier stage of the disease to be 
effective.[2, 3] Actually, there are insufficient data to support or confute this hypothesis, 
although this  meta-analysis shows that, in patients enrolled at a relatively advanced stage of 
the disease, statins are not effective in the prevention of cardiovascular events or in the 
reduction of disease progression. The efficacy of statin therapy needs to be tested in earlier 
stages of the disease when the transvalvular gradient has not yet ensued, as already suggested 
by Wierzbicki and coll., [30]  and by a study included in our meta-analysis [10]  showing that 
statins effectively delayed the progression of aortic stenosis in patients with aortic sclerosis 
and mild aortic stenosis, but not in patients with moderate stenosis. In other words, statin 
therapy as an effective preventive strategy  should now be assessed very early in patients at 
risk of calcific aortic valve disease, and certainly no later than at first diagnosis of aortic 
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sclerosis or mild stenosis; and periodic screening with transthoracic echocardiography can 
help in identifying patients at risk.  
In addition, it is possible that the discrepancy between the mild or null effects of  statin 
therapy in moderate aortic stenosis, when the disease is already at an advanced stage, and the 
more evident results that can be achieved by statin treatment in case of earlier stages of 
atherosclerotic disease (JUPITER trial) can be dissolved by the hypothesis that the maximal 
efficacy of these drugs might be achieved when they are given at earlier stages of both 
diseases, aortic stenosis and atherosclerosis.   
In conclusion, our study does not support the concept that statins may reduce the progression 
rate of calcific non-rheumatic aortic stenosis; it also strongly indicates the need for adequately 
powered, well-designed prospective randomized controlled studies in patients at earlier 
disease stage. 
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3. Mitral valve prolapse: molecular mechanisms and   targeted 
preventive therapies 
 
3.1 Anatomy of the mitral valve 
 
It was Andreas Vesalius who suggested the picturesque term ―mitral‖ to describe the left 
atrioventricular valve owing to its resemblance to a plan view of the bishop‘s mitre. 
The valvar complex comprises the annulus, the leaflets, the tendinous cords, and the 
papillarymuscles. Also important for its functioning is the left atrial musculature inserting to 
the leaflets and the myocardium to which the papillary muscles are inserted. The valve is 
obliquely located in the heart and has a close relation to the aortic valve. 
 
 
 
The annulus marking the hingeline of the valvar leaflets is more D shaped than the circular 
shape portrayed by prosthetic valves. The straight border accommodates the aortic valve 
allowing the latter to be wedged between the ventricular septum and the mitral valve. In this 
region, the aortic valve is in fibrous continuity with one of the two leaflets of the mitral valve. 
Expansions of fibrous tissues at either extreme of the area of continuity form the right and left 
fibrous trigones. 
(A) View of the base of the heart in 
anatomical orientation shows the 
spatial relations of the four cardiac 
valves. The left heart valves are 
close together whereas the right 
heart valves are separated by 
myocardium. Dotted line marks the 
limit of atrial myocardium around the 
mitral orifice.  
(B) This dissection of the heart 
viewed from the anterior aspect 
shows the close relation between 
aortic and mitral valves in situ. 
Fibrous continuity between the 
valves (blue arrows) is related to the 
nonand left coronary sinuses of the 
aorta. 
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The atrioventricular conduction bundle passes through the right fibrous trigone. The annulus 
opposite the area of valvar fibrous continuity tends to be ―weaker‖ in terms of lacking a well 
formed fibrous cord. This is the area affected in ―annular dilation‖ and also most often 
involved in calcification of the The annulus opposite the area of valvar fibrous continuity 
tends to be ―weaker‖ in terms of lacking a well formed fibrous cord. This is the area affected 
in ―annular dilation‖ and also most often involved in calcification of the annulus. With severe 
dilation, the minor axis of the valvar orifice becomes so distended that the leaflets, which are 
of fixed lengths, become unable to approximate each other.  
Distinctly different from the tricuspid valve, the mitral valve has two leaflets although some 
may argue that it has four leaflets. The corresponding terms for anterior and posterior are 
―aortic‖ and ―mural‖. The aortic leaflet hangs like a curtain between the left ventricular inflow 
and outflow tracts. When the valve is closed, this leaflet appears to form the greater part of the 
atrial floor but is approximately equal in area to the mural leaflet. With the leaflets meeting, 
the view of the valve from the atrium resembles a smile. Each end of the closure line is 
referred to as a commissure. These are designated the anterolateral and posteromedial 
commissures.  
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The free edge of the mural leaflet is often divided into three or more scallops or segments 
described as lateral, middle, and medial or assigned terms like P1, P2, and P3. Nearer the free 
edge, the atrial surface is irregular with nodular thickenings. This is also the thickest part, 
corresponding with the line of closure and the free margin.  
 
Tendinous cords attach to the underside of this area described as the leaflet‘s rough zone. The 
rough zone is broadest at the lowest portions of each leaflet but tapers toward the periphery, 
or commissure, of the closure line. The basal zone that is found only in the mural leaflet is the 
proximal area that has insertions of basal cords to its ventricular surface. Being distant from 
the ventricular wall, the aortic leaflet does not have attachments to basal cords. In normal 
valve closure, the two leaflets meet each other snugly with the rough zone and free edge in 
apposition but at an angle to the smooth zone. The tendinous cords are string-like structures 
that attach the ventricular surface or the free edge of the leaflets to the papillary muscles. 
Characteristically, the tricuspid valve has cordal attachments to the ventricular septum 
allowing it to be distinguished from the mitral valve on cross sectional echocardiography. The 
tendinous cords of the mitral valve are attached to two groups of papillary muscles or directly 
to the postero-inferior ventricular wall to form the tensor apparatus of the valve. Cords that 
arise from the apices of the papillary muscles attach to both aortic and mural leaflets of the 
Carpentier‘s classification of the 
scallops of the mitral valve leaflets 
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valve. Since cords usually branch distal to their muscular origins, there are five times as many 
cords attached to the leaflets as to the papillary muscles.  
Papillary muscles are the muscular components of the mitral apparatus. As a functional unit, 
the papillarymuscle includes a portion of the adjacent left ventricular wall. Tendinous cords 
arise from the tips of the papillary muscles. Alterations in the size and shape of the left 
ventricle can distort the locations of the papillary muscles, resulting in valvar function being 
disturbed. The papillary muscles normally arise from the apical and middle thirds of the left 
ventricular wall. Described in most textbooks as two in number, however, there are usually 
groups of papillary muscles arranged fairly close together.At their bases, the muscles 
sometimes fuse or have bridges of muscular or fibrous continuity before attaching to the 
ventricular wall. Extreme fusion results in parachute malformation with potential for valvar 
stenosis. 
 
3.2 Pathophysiology of mitral regurgitation 
 
Mitral regurgitation is defined as systolic retrograde flow from the left ventricle into the left 
atrium. All lesions that cause mitral regurgitation do so by reduction or elimination of the 
normal systolic coaptation between anterior and posterior mitral leaflets, which normally 
ensures mitral competence. Mechanisms are grossly classified as functional (mitral valve is 
structurally normal and disease results from valve deformation caused by ventricular 
remodelling) or organic (intrinsic valve lesions). They can be subclassified by leaflet 
movement (Carpentier’ s classification): type I (normal valve movement, such as annular 
dilatation or leaflet perforation); type II (excessive movement); and type III (restrictive 
movement: IIIa diastolic restriction such as rheumatic disease; IIIb systolic restriction as in 
functional disease).  
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Major causes of surgical mitral regurgitation in Western countries are degenerative (primary 
myxomatous disease, primary flail leaflets, annular calcification), representing 60–70% of 
cases, followed by ischaemic mitral regurgitation (20%), endocarditis (2–5%), rheumatic (2–
5%), and miscellaneous causes (cardiomyopathies, inflammatory diseases, drug-induced, 
traumatic, congenital). Ischaemic disease probably represents a large proportion of the non-
surgical disease burden.  
Degenerative mitral regurgitation is usually related to mitral-valve prolapse  and rarely to 
isolated mitral annular calcification. The main phenotypes of mitral prolapse are diffuse 
myxomatous degeneration (mitral-valve prolapse syndrome or Barlow‘ s disease, sometimes 
with posterior annular translocation into left atrium) or primary flail leaflets with ruptured 
chordae affecting the posterior leaflet in 70% of cases, and accompanied by myxomatous 
degeneration localised to the flail segment and generally normal valve morphology elsewhere. 
The ischaemic form of this disease rarely results from an organic mechanism (papillary-
muscle rupture) and is rarely acute.  
Papillary muscle dysfunction plays little part in the generation of functional mitral 
regurgitation, which is mostly caused by apical and inferior-papillary-muscle displacement 
due to ischaemic left-ventricular remodelling. Post inflammatory and postradiation mitral 
regurgitations have similar mechanisms. Retraction of tissue is a major limitation to 
    Causes and mechanisms of mitral valve regurgitation 
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successful valve repair. Endocarditic mitral regurgitation might be caused by ruptured 
chordae or perforations. In all causes, annular enlargement is common, is located mostly or 
exclusively on the posterior part of the annular circumference, and surgical repair almost 
always requires annuloplasty. 
Physiology of functional mitral regurgitation is even more complex than that of organic mitral 
regurgitation since ventricular dysfunction predates the regurgitation. Nevertheless, functional 
mitral regurgitation further increases atrial pressure, which leads to pulmonary hypertension 
and heart failure. Progression or recurrence after annuloplasty is weakly related to annular 
enlargement but strongly to increased mitral tenting caused by ventricular remodelling, 
papillary-muscle displacement and increased chordal traction; however, rates of progression 
are unknown. 
In view of the experimental nature of medical and interventional treatments for mitral 
regurgitation, surgery is the only treatment recommended by management guidelines. The 
benefit of early surgery (ie, valve repair in asymptomatic patients) versus a watchful wait was 
suggested in observational studies but is controversial. Patients with organic mitral 
regurgitation who have developed severe symptoms (class III or IV), heart failure, or signs of 
overt left-ventricular dysfunction (ejection fraction <60% or end-systolic dimension ≥40–45 
mm) have an immediate high risk and therefore prompt surgery—repair (preferable) or 
replacement is indicated. Even with advanced heart failure or ventricular dysfunction, 
contraindications to surgery are rare as long as mitral regurgitation remains severe, 
emphasising the importance of quantitative assessment of disease. Such rescue surgery is 
indispensable, but is not the preferred timing for surgery in organic disease. Indeed, patients 
who need to be operated on at such a late stage of their disease have increased mortality after 
surgery. This outcome emphasises the importance of early detection and assessment of mitral 
regurgitation. In functional regurgitation, rescue surgery is the most frequent surgical 
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indication, but consideration should be given to surgery in symptomatic patients before heart 
failure becomes intractable.  
Patients with no or minimum symptoms at baseline cannot expect substantial symptomatic 
improvement. Those with functional mitral regurgitation are rarely candidates for restorative 
surgery while asymptomatic but might be suitable for valve repair if coronary artery bypass 
grafting is necessary independently of the mitral regurgitation. In organic regurgitation, 
postoperative outcome studies in patients with no or minimum symptoms before surgery show 
restoration of life expectancy, emphasising the importance of this approach. Patients who are 
asymptomatic but had either reduced functional capacity by objective exercise testing, 
hormonal activation, or paroxysmal atrial fibrillation are specific but not exclusive candidates 
for restorative surgery. 
To ensure success of such restorative surgery, important requirements form the basis of 
advanced mitral-valve repair centres. 
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3.3 Biology of mitral valve prolapse: the harvest is big, but the 
workers are few 
 
INTRODUCTION 
Mitral valve prolapse, i.e. abnormal systolic protrusion of mitral valve leaflets into the left 
atrium, represents a common cause of severe mitral regurgitation (MR) and it often requires 
surgical correction, especially in people living in industrialized countries [1,2]. Its average 
prevalence in the adult population is 2% to 8%; thus, MVP is expected to occur somehow in 
the life course in approximately 7.2 million individuals in the United States and in over 144 
million worldwide [3]. Besides, a marked effect on its spread and severity is played by aging 
[4]: for instance, important mitral anatomical changes are found at post-mortem in 
approximately 5-7% of elderly people, with males showing about twice the risk of females of 
developing severe regurgitation when ageing [5]. With regard to younger people, some 
studies show that both genders are equally affected, whereas others document a female 
preponderance [6]. 
At difference from what happens in chronic ischemic mitral regurgitation (which is a 
secondary pathologic entity resulting from a variable combination of infarction-induced 
subvalvular remodeling with subsequent leaflet tethering and annulus dilatation/flattening) 
[7,8], this disease is, in the majority of cases, a primary condition characterized by a 
progressive myxomatous degeneration of the mitral valve leaflets and of chordae tendinae 
[1,2,9]; it represents a slowly developing process which usually shows a benign course, as  
less than 10% of all prolapsing mitral valves progress to severe regurgitation requiring 
surgery during their lifetime [10]. Nevertheless,  sometimes, people affected by worsening 
mitral regurgitation suffer from a series of symptoms most represented by dyspnoea and 
palpitations related to secondary onset of supraventricular tachiarrhythmias, conditions that 
usually require repeated hospitalization and different diagnostic tests execution. Given the 
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wide diffusion of MVP, this translates into very high costs for health organizations in the 
adult population, even if only a small portion of patients will eventually need surgical 
treatment.  
Although clinical features and  pathophysiology of  MVP are known since several decades, 
limited data are available regarding biological mechanisms or biochemical perturbations 
possibly implicated in the progression of this valve disease. 
The present study is aimed at summarizing the current knowledge (including preclinical and 
clinical evidence) about molecular and biological bases of  mitral valve myxomatous 
degenerative disease in order to better understand the continuum of the process and to identify  
potential therapeutic targets and preventive approaches.  
We will also focus on the description of some biochemical alterations primarily highlighted in 
patients affected by MVP who present with a cohort of symptoms (only partially shared with 
simple MVP) that are not directly related to the hemodynamics of mitral regurgitation. This 
condition, known as mitral valve prolapsed syndrome (MVPS), is characterized by chest pain, 
dysrhythmia, anxiety, insomnia and syncope [11], and is associated with a certain degree of 
adrenergic and renin angiotensin aldosterone (RAA) system impairment, a condition showing 
only partially common features with pure-isolated MVP disease. 
 
GENETIC 
 
Several studies have shown that MVP can be familial, sporadic, or can occur secondary to a 
variety of connective tissue disorders such as Ehlers-Danlos syndrome, Sticker syndrome and 
adult polycystic kidney disease [11]. Also, in recent years there has been a significant effort in 
identifying genetic profiles related to MVP, especially through the use of linkage analysis, in 
order to define a genetic screening tool available for clinicians. These studies, however, have 
identified  a specific subset of familial primary MVP, whose inheritance appears to be 
attributable to an autosomal dominant mode with variable expression [12]. Familial genetic 
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linkage studies were performed with the aim of mapping possible loci for MVP occurrence, 
and have shown  that several genes located on chromosomes 11,13,16 and X (some of them 
being partially related to human leukocyte antigens, HLA) have a weak association with the 
familial form of this disease (12), with the possible exception of the locus MMVP3 on 
chromosome 13 which is strongly associated with the familial variant of MVP [13] and of the 
X-chromosome-gene coding for filamin A (a cytoskeleton protein) which seems to be 
responsible for X-linked form of Barlow‘s disease [14]. The possibility, however, that these 
preliminary data can be extrapolated beyond the context of the rare entity of familial MVP 
has not yet been verified.  
An alternative hypothesis, which considers the somehow obvious concept that familial MVP 
arises from a heritable collagen gene defect, has been tested through the analysis of its 
segregation pattern in affected families [15]. In contrast to what expected, the trait was shown 
not to be linked to COL1A1, COL1A2, COL3A1 or COL5A2 loci, which suggests that valve 
abnormalities of familial MVP  are not caused by a structural defect in any of these genes. 
Interestingly, a more definite role seems to be played by specific mutations in the genes for 
Transforming Growth Factor Receptor I and II (TGFBR), which appear to be associated with 
particular phenotypic expression and cardiovascular (including MVP) and skeletal features in 
the context of general connective tissue disorders which are only partially shared with the 
classic form of Marfan Syndrome, thus allowing the proposition of new disease entities 
named Marfan type II, Loeys-Dietz, Shprintzen-Goldberg and Furlong syndromes [16]. 
Again, the real importance of TGFBR in the development of sporadic MVP beyond the 
Marfan –like milieu needs further evaluation.  
In addition, several studies have tried to assess possible links between a variety of gene 
polymorphisms and sporadic non familial MVP, focusing on genetic factors implicated in 
extracellular matrix remodeling, collagen metabolism, RAA system and haemostasis. 
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Concerning collagen metabolism, in three different studies Chou et al. have addressed both 
genotype distribution and allelic frequencies of these genes in one hundred MVP patients 
compared to, respectively, 140 [17], 243 [18], and 106 [19]  age and sex – matched normal 
control subjects. These studies show a significant association between sporadic MVP onset 
and certain genotypes of fibrillin-1 gene (exon 15 TT and 27 GG), of collagen (COL3A1 exon 
31 GG) [17,18] and of urokinase – plasminogen activator (PLAU) (a protein-system acting as 
a trigger in initiating metalloproteinases pathway for extracellular matrix degradation in aortic 
aneurysms and consequently perhaps involved in collagen turnover). This observation results 
in partial contrast with previous findings concerning familial MVP [16] that did not show any 
role of these genes in disease occurrence. In addition, the significant allelic frequency 
difference found (in particular regarding COL3A1 exon 31 polymorphism, whose p-value was 
highly significant) suggests  a pivotal role in MVP occurrence and progression, since these 
allelic variants render fibrillin 1 and collagen less resistant and more extensible, similarly to 
what happens in connective tissue disorders such as Marfan and Ehlers-Danlos syndromes 
[17,18,19]. 
Unfortunately, all these  associations derive from studies carried on geographically and 
statistically limited population subsets, leaving still open the question whether they could 
have a general meaning.  
In addition to collagen strength and resistance to fatigue, the attention of investigators pointed 
on the assessment of the possible role of some genetic characters in accelerating mitral valve 
disease progression, suggesting that matrix metalloproteinases-3 (MMP-3) promoter 
haplotype may represent a marker of adverse and rapid pathologic course, leading to fast 
increasing valve regurgitation and to consequent left ventricular remodeling process [20].  
Finally, the role of RAA system has been explored, especially  in patients affected by the 
additional symptoms of MVPS, through the assessment of the existence of a genetic link 
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between MVP and a higher allelic frequency of angiotensin converting enzyme (ACE) II 
genotype [21] and of A-C (1166) polymorphism of the angiotensin II type 1 receptor gene 
[22]. Specifically, the presence of ACE II genotype provides an Odd-Ratio (OR) for MVP 
onset risk of 2.14, whereas the OR in favor of carrying the C1166 allele of angiotensin-1 
(AT1) receptor is four times greater for MVP patients than for controls. All these findings  are 
consistent with the hypothesis that ACE system is involved in the occurrence/progression of 
this disease, as documented both in Asiatic and European populations. The contribution of 
other neuroendocrine perturbations still needs further investigation. 
In conclusion, both the genes involved in tissue strength and in tissue remodeling may 
sensibly affect MVP occurrence; RAA system also seems to play a key role, especially in the 
context of MVP syndrome. Further validation from additional studies is warranted, especially 
because genetic data have been obtained in relatively  limited numbers of patients. 
 
HAEMOSTASIS AND PLATELET FUNCTION 
 
The clinical observation of an higher incidence of thromboembolic events of unidentified 
origin in patients affected by MVP with respect to general population has been documented 
since 1980 by Barnett et al. [23], with a particular emphasis on the occurrence of repeated 
episodes of cerebral ischemia in specific subsets of MVP patients who, for unknown reasons, 
are greatly predisposed to these body weakening complications. Although available evidence 
in favor of the existence of a substantial link between MVP and thromboembolism is strong  
[24-27], some Authors are critical  with these findings [28]; in addition, epidemiologic studies 
have raised several questions on the association between MVP and cerebro-vascular 
complications documenting that stroke incidence in young patients  seems to be unrelated to 
the echocardiographic diagnosis of mitral leaflet prolapse when the degree of valve 
insufficiency is not relevant [29] and that MVP patients with angiographically normal 
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coronary vessels fail to show a pro-thrombotic status [30]. This is –however- somehow in 
contrast with several other studies, which support an association between MVP and 
perturbations of the haemostatic pathways, although evidence in favor and against this 
association is  available in literature [24-28,31,32,33,37,39].  
MVP disease has been associated with some degree of platelet and haemostatic abnormalities 
in the early eighties [31,32,33], but a consensus on  the main haemostatic perturbations 
associated with this disease  was never reached; also, it is unclear whether MVP represents 
the cause or the effect of these abnormalities.  Some Authors documented  a slightly 
augmented platelet activation (assessed both in plasma before and after stimulation of 
platelets with  conventional agonists by measuring  beta-thromboglobulin and platelet factor 4 
[25,34], whereas  Others  have shown a somehow reduced platelet activation, as evidenced by 
the expression of P-selectin after stimulation of platelets [24]; in addition, an increase in 
thrombin generation has also been found in patients affected by MVP [24]. Interestingly, a 
higher degree of valve insufficiency was associated with more marked haemostatic 
perturbations,  suggesting that the disease per se is not responsible for the activation of 
platelets, which is, otherwise, secondary to the altered patients‘ haemodynamics (whose entity 
is directly proportional to the increase of regurgitant blood fraction) or to abnormalities 
occurring at the platelet level directly on the surface of diseased  valves [24]. It should be 
mentioned, however, that other studies reached completely opposite conclusions, e.g. no 
systemic beta-thromboglobulin increase in neurologically asymptomatic MVP patients [35] 
nor major platelet function alterations [36], with the only exception of impaired aggregation 
[37], consisting in a slight decrease of basal platelet aggregation rate in a relatively limited 
number of patients. 
It has also been reported that  about one third of asymptomatic patients shows  increased 
levels of platelet factor-4 [34] or of beta-thromboglobulin levels [36], as well as increases in 
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von Willebrand factor (vWf) antigen or fibrinopeptide A [37]. Even if no clinical study 
provides evidence for this hypothesis, we can envision that also in patients who did not 
experience thromboembolic complications, there might be a subgroup at highest risk for these 
complications. Walsh et al. documented that the increased platelet coagulant activity  (e.g. the 
ability of platelets to activate factor XII  thus promoting the interaction among factors XIa, 
VIII, IX and X, leading to the initiation of  coagulation) and the augmented proportion of 
circulating platelet aggregates occur concomitantly with clinical thromboembolic phenomena, 
leading to transient visual obscurations and retinal or cerebral ischemic attacks [26]; even 
platelet survival time [27] and global fibrinolytic capacity [38], which provides information of 
the global fibrinolytic system degree of activity, are significantly shortened in those patients 
with MVP developing systemic embolism or presenting an history of transient ischemic 
attacks. 
In one trial the fibrinolytic system has been assessed in MVP patients in comparison with  
individuals affected by nonrheumatic calcific aortic valve stenosis. In this study, higher 
plasma fibrinogen levels were found in both groups of patients when compared to ―normal‖ 
population values. Instead, mitral patients presented lower fibrin D-dimer plasmatic 
concentrations than aortic and control subjects; these findings seem to be consistent with the 
existence of lesser intravascular clotting in MVP with respect to calcific aortic stenosis and, 
consequently, with different mechanisms implicated in clinical thrombogenesis [39]. 
A certain degree of common rheologic similarities involving aortic and mitral diseases is, 
however,  further supported by Francis, who investigated platelet aggregation in response to 
epinephrine and ADP stimuli in patients undergoing valvular heart surgery in comparison to 
patients with coronary artery bypass grafting (CABG): interestingly, abnormal ADP-related 
occlusion is more frequent in valvular patients, reflecting a pre-existing high-shear damage to 
platelets that renders them refractory to subsequent shear activation and aggregation [40]. 
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Again, this phenomenon appears to be the consequence, rather than the cause, of MPV. In 
partial contrast with previous data are the results reported by Olsen et al. who studied 
haemostatic variables in the main canine model of MVP pathology, referring  a form of 
platelet dysfunction identified at high shear rates regardless of mitral regurgitation gravity and 
associated to a qualitative vWF defect; at variance to what reported for human subjects, dogs 
with mitral regurgitation had enhanced platelet aggregation compared to controls [40,41]. 
Interestingly, in a previous study, the same Authors performed a subgroup analysis stratifying 
animals according  to the degree of valve insufficiency: they reported an increase in 
circulating fibrinogen concentration (directly related to left ventricular end diastolic diameter 
and left atrial to aortic root ratio) among all dogs, and they also observed that  the severity of 
mitral regurgitation was proportionally associated with low plasma vWF concentration, most 
likely due to the  loss of vWF high molecular weight multimers (HMWMs) [42].  This, 
however,  needs to be confirmed in humans. In this context, it is worth mentioning that a 
similar decrease in the circulating levels of  HMWMs of vWF was reported in patients 
affected by aortic stenosis due to the action of ADAMTS-13, a matrix metalloproteinase that 
acts on vWF preferentially under conditions of high shear stress, as it happens through a 
stenotic valve orifice or –possibly- in case of regurgitant mitral valves. In the context of 
calcific aortic stenosis, such phenomenon may lead to significant bleeding episodes (often 
classified as Heyde‘s syndrome), which are also documented in a minority of MVP patients 
[33,43,44], which is suggestive for a common underlying pathogenetic mechanism. The 
reasons why in MVP haemostatic alterations preferentially result in thromboembolic rather 
than bleeding events, as it occurs in aortic stenosis, are not known. Finally, Girolami et al.  
documented that some rare congenital clotting defects (namely the combined phenotypic 
deficiency of FX and of FVII) are accompanied by a higher percentage, with respect to 
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general population, of a cohort of haemostasis-unrelated abnormalities, including mitral 
myxomatous degeneration [45]. 
In conclusion, currently available data suggest possible links between MVP and perturbations 
of the clotting and fibrinolytic system and of platelet function as well, which are potentially 
linked to thromboembolic complications occurring in this disease. Evidence currently 
available, however, is confined to some animal studies or to studies carried out many years 
ago, a feature limiting  their immediate translation  into clinical practice. Finally, another 
important issue concerns the timing of the occurrence of these perturbations, as it is unclear if 
they anticipate or follow  MVP onset. 
 
INFLAMMATION 
 
The potential role of inflammatory processes in relation with MVP onset has seldom been 
studied; only one recent study [46], carried out in six mitral nonrheumatic prolapsing valves 
specimens obtained from patients undergoing mitral valve repair, addressed apolipoproteins 
and inflammatory cells detection in this disease. In comparison to stenotic aortic valves, both 
mitral and aortic regurgitant valves showed a significant lower degree of inflammatory 
infiltrates (composed by lymphocytes positive for CD3, CD20 and CD68 antigens and 
macrophages) and of apolipoprotein A-1 and B deposition. These preliminary findings 
suggest that, at variance with  what happens in aortic stenosis onset and progression [47], 
inflammation and cholesterol metabolism may not be the main actors in the course of this 
pathology. Further studies, however, are needed to confirm this hypothesis.  
 
OXIDATIVE STRESS AND ENDOTHELIAL FUNCTION 
 
The hypothesis that a primitive increase of oxidative stress goes along with MVP 
development was first tested several years ago by Arocha et al. who studied the production of 
malondialdheyde (MDA) in forty asymptomatic patients who were found by chance to be 
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affected by myxomatous mitral disease at echocardiography [36]. They documented 
significantly augmented plasma MDA levels in MVP patients with respect to a control group 
of 17 age and sex matched controls. Animal studies also show that a certain degree of 
oxidative state impairment occurs, detected both at a systemic and at a local level; in 
particular, there is an  increased NADPH-diaphorase activity and subsequent augmented nitric 
oxide synthase (NOS) expression in areas of mitral valve showing myxomatous changes [48] 
and decreased plasmatic Nox concentrations directly proportional to the severity of mitral 
insufficiency [49]. This suggests that nitric oxide (NO) may play a role in MVP pathogenesis; 
in addition, endothelial dysfunction may also develop early in the course of valve disease, and 
it seems to worsen as regurgitation becomes more relevant. This has been further confirmed 
by the finding of augmented NO release in regions of early prolapsing porcine mitral valve 
leaflets presenting accumulation of mucopolysaccharide deposits and defraction of the valve 
structure (and consequently more prone to myxomatous degeneration and prolapse), thus 
suggesting local changes of both endothelial and inducible NOS expression [50]. Moreover, 
another study collecting postmortem canine mitral valve specimens with clear macroscopic 
signs of myxomatous degeneration showed that diseased areas with collagen degeneration and 
fibrosis had higher endothelin-receptor spreading, whose density within, as well as, on the 
mitral leaflets was significantly associated with the degree of myxomatous disease [51]. 
Unfortunately, all available data, with the exception of the study by Arocha, concern pre-
clinical MVP models, which consequently still need confirmation in humans.  The increase in 
oxidative stress, however, is not a peculiarity of MVP; in fact, in nonrheumatic stenotic aortic 
valve disease the markers of oxidative stress are increased within the valve tissue [47]; and a 
recent study by Rabus et al. suggests that systemic oxidative stress increase can be found both 
in aortic and mitral valve disease, of both  rheumatic and nonrheumatic etiology [52]. 
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These data highlight a potential role, although probably not disease-specific, of both oxidative 
stress and endothelial dysfunction in MVP, requiring additional substantiation from future 
studies; finally, even in this case, the question if the activation of these pathways is causative 
or not is still open. 
 
EXTRACELLULAR MATRIX REMODELING AND BONE METABOLISM 
 
It is recognized that myxomatous degeneration is the pathological substrate of MVP, whose 
main feature is represented by redundant leaflets; floppy valves likely result from 
mechanically inadequate extracellular matrix (ECM) status, particularly collagen, thereby 
allowing stretching of the leaflets [5,53]. More in detail, at the ultrastructural level, several 
studies have shown fragmentation, splitting, swelling and coarse granularity of some collagen 
fibrils and a spiraling twisted appearance of others in diseased valves [54,55,56,57]; changes 
in elastic fibers, including an increase in the content of elastic tissue, have also been reported 
[58].  
Nevertheless, the real mechanisms responsible for the ECM defect and/or reparative processes 
that strengthen its faulty status are still uncertain. Basing upon the hypothesis that, as in other 
tissues, ECM turnover depends on a dynamic balance between synthesis and degradation that 
occurs through the action of matrix metalloproteinases (MMP) and cysteine endoproteases, 
Rabkin et al. evaluated the role of valvular interstitial cells and catabolic enzymes in the 
pathogenesis of myxomatous degeneration, documenting that myxomatous interstitial cells 
show features of activated myofibroblasts expressing higher levels of collagenases (MMP-1, 
MMP-13),  gelatinases (MMP-2, MMP3), and other proteolytic enzymes (cathepsin S and K)  
when compared with analogous normal mitral valves obtained at autopsy [59].  The role of 
altered ECM turnover and metabolism in determining leaflets prolapse was later confirmed by 
another study [60] comparing molecular and histological features in normal and ruptured 
chordae tendinae cordis (CTC) conditioning severe mitral regurgitation: in particular, the 
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Authors pointed their attention on the differential local expression of tenomoduline (a recently 
isolated anti-angiogenic factor) measured in various areas of CTC. They showed that 
tenomoduline is locally absent in the ruptured zones of chordae, favoring abnormal vessel 
formation also in combination with enhanced expression of vascular endothelial growth 
factor-A (VEGF-A). Moreover, differently from what observed in normal or non-ruptured 
areas, higher numbers of inflammatory cells positive for CD11b, CD14 and vimentine and 
with an augmented expression of MMP-2 and 13 were detected in association to the  
downregulation of tenomoduline. The role of tenomoduline and of the different pathways 
related to this molecule could be of great clinical interest, since we have to keep in mind that 
the crucial passage from simple elongated chordae to their rupture frequently coincide with 
symptoms onset and consequently with aprobable surgical indication. 
Interestingly, changes in metalloproteinase expression was also found in specimens of left and 
right appendages taken from patients undergoing mitral valve surgery, which showed 
downregulation of MMP-1 and -9 with respect to patients undergoing CABG; at variance, 
MMP-2 and TIMP-1, -2 and -4 expression were similar.  This suggests that, although sensibly 
different in terms of activation or repression, the involvement of metalloproteinases in MVP 
is not limited to the mitral valve but can also occur in other heart structures [61]. 
Moreover, the influence of interstitial cells constituting valve ECM on MVP onset and 
development has also been documented in some animal models and in human specimens: in 
fact, mesenchimal cell activation (α-SMA positive cells overexpression) [62] and phenotype 
transformation (towards CD34+ fibrocytes, [63] occur throughout the valve leading to 
dramatic cellularity increase and metalloproteinases  secretion (MMP-2 and -9), whose degree 
of expression directly correlates with disease severity [64]. In addition, the role of CD34+ 
fibrocytes is of particular interest; this cell population, in fact, is able to synthetize MMP-9 as 
well as collagen I and III (constituting a crucial factor in MVP pathogenesis) and seems to be 
 85 
responsible for tissue repair subsequent to mechanical alteration of the mitral valve [63].  
Cellular proliferation, associated to tissue redundance, appears to be augmented even in 
genetically engineered mice resembling patients affected by Marfan Syndrome and MVP, 
thus providing critical insight into the pathogenetic mechanism of such abnormalities in 
syndromic and perhaps non-syndromic variants of mitral valve disease [65]. In particular, Ng 
et al documented that mitral valves isolated from fibrillin-I deficient mice exhibit post-natally 
acquired alterations in ECM architecture secondary to augmented cell proliferation, decreased 
apoptosis and excess Transforming Growth Factor- β (TGF-β) activation and signaling. 
Numerous TGF-β related genes, such as βIGH3, endothelin I and tissue inhibitor of MMP-1 
(TIMP 1) resulted overexpressed; since they are all involved in cellular proliferation and 
survival, it is plausible to hypothesize their relevant contribution to myxomatous degeneration 
development [65]. 
Once more, the  issue whether such phenomena  play a consistent role even in humans is still 
open. 
Only recently, mitral valve degeneration has been associated to an osteoblasic differentiation 
process mediated by the low-density lipoprotein receptor-related protein 5 signaling pathway 
that might cause leaflet tickening. In fact, Caira et al have highlighted some common features 
that  characterize two frequent valvular pathologies (aortic stenosis and MVP), since an 
endochondral bone differentiation is evident in both, but it is expressed as cartilage in mitral 
valves and as pure bone in the aortic ones [66]. Such conclusion is  also consistent with the 
crude ―in vivo‖ aspect of valve leaflets inspected at surgery, as the stenotic aortic ones are 
often fused and deeply calcified, while mitral ones seem fibroelastic ―entities‖ flopping into 
the left atrium. 
Taken together, currently available evidence suggests that CTC rupture is not accidental, but 
can occur when and where CTC are weakened by neoangiogenesis, MMP activation and 
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infiltration of inflammatory cells secondary to the loss of or damage to the tenomoduline 
layer, a phenomenon perhaps subsequent to locally increased mechanical stress or to primitive 
inflammatory events.  
 
MVP AND MVPS: A COMMON BIOLOGIC BACKGROUND ? 
 
As stated before, a subgroup of patients affected by MVP presents a number of complaints 
that seem to be completely independent from their primary cardiac disease, establishing the 
so-called mitral valve prolapse syndrome. Typical clinical manifestations of this pathology 
include unexplained chest pain (not related to atherosclerosis or to other evident causes), 
palpitations, fatigue, exercise intolerance, insomnia, dizziness and panic attacks which are so 
relevant to induce psychiatric-like disorders in affected patients. Such symptoms often have a 
great impact on patients‘ daily life, probably more than those strictly related to valve 
dysfunction ―per se‖, since, as usual,  they are underestimated or misunderstood by 
physicians; therefore,  we believe that an effort in clarifying the pathogenesis of these 
complaints and the reason why not all affected people share the same symptoms needs to be 
performed, considering also the fact that only ―spot‖ evidences are available in medical 
literature. 
In particular, Authors have focused their attention on enhanced adrenergic activity as a 
possible cause, whereas others have implicated  magnesium deficiency  or perturbations of  
the RAA system.  
Renin-angiotensin-aldosterone system. An impairment of RAA has been found even 
in the early phases of degenerative mitral disease in dogs, when the animals are still 
asymptomatic or mildly symptomatic; this excludes the role of  heart failure secondary to MV 
disease in the up-regulation of  RAA. In particular, both plasma renin activity (PRA) and 
aldosterone concentration are significantly higher compared to controls  [67], and the levels of 
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the  serum angiotensin-converting enzyme (ACE) activity are also increased [68,69]. The 
concomitant finding of normal concentrations of endothelin-1, atrial natriuretic peptide and 
arginine vasopressin, all  peptides of pathophysiologic importance in congestive heart failure 
(CHF), further supports the concept that the valve disease itself, and not its clinical sequelae 
ultimately leading to heart failure, underlie RAA activation.  
In translating similar concepts into ―human patients‖, many Authors have shown  various 
degrees of RAA impairment in MVPS patients: in detail, it has been shown that these patients 
display abnormal regulation patterns of RAA during upright posture and volume depletion, 
consisting in a greater increase of  PRA and in the absence of changes in plasma aldosterone 
levels compared to controls [70,71].  
Adrenergic activity. The existence of an autonomic dysfunction and of an enhanced 
adrenergic tone has also been investigated in  both isolated MVP and in MVPS. Several 
Authors have shown abnormal adrenergic reactivity (which may explain the  RAA system 
impairment too), as suggested by the presence, in MVPS patients, of higher 24-hour urinary 
vanillilmandelic acid (VMA) excretion, of greater resting heart rate in MVPS young men [70] 
and of higher epinephrine and norepinephrine levels in plasma [71]. Excessive vagal tone and 
α-adrenergic hyperactivity have also been documented [72]. Interestingly, similar 
neuroendocrine alterations have been shown in pure MVP patients without an history of 
autonomic symptoms. And MVP patients also exhibit a greater incidence of syncope (when 
compared to controls), more orthostatic hypotension during quiet standing and loss of the 
normal decrease with age in vagally-mediated heart rate variability during deep breathing. In 
addition, a lower 24-hour epinephrine excretion was observed, which is suggestive of an 
hidden autonomic dysfunction not clinically evident  associated with the presence ―per se‖ of 
the cardiac lesion [73]. 
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Finally, evidence is currently available concerning the association between increased 
adrenergic state and augmented plasmatic values of atrial natriuretic factor in MVPS, 
especially in hypovolaemic individuals [71,74]; the interplay between these two neuro-
endocrine disorders may account for some of  the addictive symptoms, by determining the 
imbalance between sympathetic and parasympathetic system, the altered RAA response to 
orthostatic stimulus and the volemic and venous flow reductions.  
Hypomagnesemia. The existence of a strong relation between MVP and  
hypomagnesemia  is a rather old concept clearly assessed both from a veterinary standpoint 
[69] (tested, once more, in Cavalier King Charles spaniels dogs without evidence of heart 
failure) and from a clinical one. Studies performed in patients suffering from accessory 
symptoms of MVPS show that decreased serum magnesium represents a common feature and 
that supplementation of this ion leads to a substantial improvement in the clinical picture 
along with the reduction in cathecolamine excretion [75]. Additional data indicate that plasma 
magnesium concentration does not correlate with MVP severity and degree of regurgitation 
[69]. Instead, it is paralleled by low total intracellular erythrocyte magnesium levels [76]. 
Taken together, these data suggest that electrolytic unbalance and autonomic dysregulation 
represent two of the main players in MVP, being a potentially therapeutic target to mitigate 
auxiliary symptoms onset and perhaps disease progression. A major issue, however, still 
needs to be addressed. The main question is whether a continuum exists starting from the 
isolated MVP towards the clinical picture of MVPS and whether this is paralleled by 
progressively increasing biologic perturbations. 
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CONCLUSIONS  
 
At variance with coronary artery disease or with  calcific aortic valve stenosis, and in spite of 
its high prevalence, historically, myxomatous degenerative mitral valve disease has always 
been ignored or, at best, underestimated from a biological point of view.  
We have reviewed here currently available evidence concerning the biological features of 
MVP. Data show that current knowledge about MVP  is limited to somehow isolated spots 
which  suggest a possible role of inflammation, oxidative stress, haemostasis and a potentially 
prominent role of extracellular matrix remodeling in mitral valve disease genesis and 
progression. Unfortunately, a deep comprehension of the pathways involved and the certainty 
whether they represent simple associated elements, real protagonists, true causes or only 
consequences of the pathology still lack.  
On the other hand, these preliminary data are, undoubtedly, a starting point worthy of deeper 
investigation, which will allow, in the future and if widely confirmed, to identify early 
pharmacological tools and targeted therapeutic strategies, in order to achieve a slackening of 
the disease progression or even a slight regression of this probably multifactorial process. 
Indeed, as, in the majority of cases, there is a long time-gap between MVP diagnosis (often 
made by chance because of lack of symptoms) and the occurrence of ―full maturation‖ with 
consequent mitral valve repair need, we can hypothesize that, for patients who receive this 
diagnosis at an early stage and  who are for this reason strictly echocardiographically 
monitored, a targeted drug therapy  with some class of drugs already available (e.g. statins, 
angiotensin-converting enzyme inhibitors, angiotensin-2 receptors blockers, beta-blockers or 
anti-proliferative molecules), or with drugs newly developed to this purpose,  may be useful.   
Further prospective studies are eagerly needed to assess if this way is valuable of 
consideration, but we expect and hope that in a near future more knowledge concerning this 
 90 
area will be available, as our current surgical therapy of MVP can only mechanically correct 
the defect of the valve but not the underlying molecular mechanisms.    
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4. Oxidative stress and valve disease: a new actor in the 
field?      
 
4.1 Oxidative stress and nitric oxide pathways in adult cardiac 
surgery patients: a comparative study 
 
INTRODUCTION 
Oxidative stress represents an imbalance between the generation of reactive 
oxygen species and the ability of cells and tissues to readily detoxify them 
leading to organ damage and dysfunction. Although the role of oxidative stress 
and its relation to nitric oxide pathways derangements in cardiovascular diseases 
such as atherosclerosis, coronary artery disease, diabetes and heart failure is well 
known [1-3], much less information are available concerning patients 
undergoing adult cardiac surgery [4], especially for patients with heart valve 
disease.  Also, previous studies on patients affected by valve disease have been 
much more focused on the presence of imbalances in valve tissue and not in the 
circulating levels of markers of oxidative stress and of nitric oxide pathways 
derangement [5, 6]; in other words, little is known concerning oxidative stress 
and nitric oxide pathways in patients who are undergoing adult cardiac surgery, 
especially concerning possible differences that could be related to different 
diseases (e.g. coronary vs. valve diseases).  The aim of this study was then to 
evaluate oxidative stress and nitric oxide pathways markers in patients 
scheduled for isolated coronary bypass surgery, aortic valve replacement for 
calcific nonrheumatic aortic stenosis, and mitral valve repair for degenerative 
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mitral insufficiency, that are the three most common adult cardiac surgical 
procedures performed in adults of western countries, and to ascertain whether 
there are differences with healthy subjects and within the different patient 
populations.   
PATIENTS AND METHODS 
Patients 
One hundred sixty-five consecutive patients candidates to undergo an elective, 
isolated adult cardiac surgical procedure (coronary artery bypass (CABG, n=63), 
aortic valve replacement for calcific nonrheumatic aortic stenosis (Aortic, 
n=51), mitral valve repair for degenerative mitral valve regurgitation (Mitral, 
n=51)) referred to our hospital were enrolled over a six-months time period 
(January 2011 – May 2011). Valve lesions were classified on the basis of 
echocardiographic and surgical findings.  
Healthy subjects with cardiovascular risk factors (Controls, n = 33) were 
enrolled from those attending the clinic for global control of cardiovascular risk 
at Centro Cardiologico Monzino IRCCS. The clinical features of Controls, 
CABG, Aortic and Mitral patients are reported in Table 1. 
All patients were assessed with detailed medical history, physical examination, 
EKG and echocardiography before scheduled surgery; for patients candiates to 
surgery, blood and urine collections were performed within 1 to seven days 
before surgery, and before coronary angiography, whereas Controls underwent 
samples collection at a scheduled follow-up visit.  
 99 
Informed consent to participate to this observational study, which was approved 
by CCM Institutional Review Board, was obtained by all patients.  
 
Oxidatve stress and nitric oxide pathways markers. 
In this study we have assessed the following markers:  
Oxidative stress: whole blood reduced glutathione(GSH)/disulphide 
glutathione(GSSG) ratio (GSH/GSSG); urinary 8-iso-prostaglandin F2α  (8-iso-
PGF2α). 
Antioxidants: plasma vitamin E (α-tocopherol, γ-tocopherol), and whole blood 
GSH. 
Nitric oxide pathways: plasma arginine (Arg), asymmetric dimethylarginine 
(ADMA), symmetrical dimethylarginine (SDMA), Arg/ADMA ratio, 
Arg/SDMA ratio. 
 
Sample collection 
Whole blood: peripheral blood sample was drawn from patients and controls 
while fasting, into tubes containing EDTA (9.3 mM; Vacutainer Systems, 
Becton Dickinson, Franklin Lakes, NJ, USA) kept on ice and immediately 
precipitated with 10% trichloroacetic acid (Sigma-Aldrich, St Louis, MO, USA) 
in1 mM EDTA solution. After centrifugation at 10,000xg for 10 min at 4°C, the 
supernatant was stored at -80°C until analysis.  
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Plasma: EDTA-anticoagulated blood was centrifuged at 3000 g for 10 min at 
4°C within 30 min after being drawn. Plasma was separated and aliquots were 
stored at -80°C until analysed. 
Urine: an overnight urine collection the night before surgery or the night before 
visit  was carried out and samples stored at -80°C until analyzed. 
GSH and GSSG 
Levels of GSH and GSSG where determined in whole blood by liquid 
chromatography – tandem mass spectrometry (LC-MS/MS) method. Prior to 
analysis samples were thawed and diluted 1:20 or 1:400 with 0.1% formic acid. 
The separation of analytes was conducted on a Luna PFP analytical column 
(100x2.0 mm, 3 µm, Phenomenex, Torrance, CA, USA) eluted at 35°C under 
isocratic conditions at 2 µL/min by 1% methanol in ammonium formate 0.75 
mM adjusted to pH 3.5 with formic acid. LC-MS/MS was performed by Accela 
HPLC system coupled with a triple quadrupole mass spectrometer TSQ 
Quantum Access (Thermo Fisher Scientific, San Jose, CA, USA) using 
electrospray ionization source and multiple reaction monitoring (MRM) in 
positive mode. The MRM for GSH (m/z 308.1→m/z 76.2 + 84.2 + 161.9) and 
GSSG (m/z 613.2→m/z 230.5 + 234.6 + 354.8) were performed with collision 
energy optimized for each compound. Data were obtained after comparison with 
calibration curves using GSH and GSSG pure standard solutions (Sigma-
Aldrich, St. Louis, MO, USA). The intra- and inter-CVs % obtained with 
standard samples were <5% for the both the analytes considered The limit of 
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detection of GSH was 0.031 µmol/L; it was 0.008 µmol/L for GSSG. Levels of 
GSH and GSSG were corrected for hemoglobin and expressed as µmol/g Hb as 
glutathione is mainly contained in erythrocytes.  
 
Isoprostane determination 
Urinary 8-iso-PGF2α was detected by LC-MS/MS method according to Cavalca 
et al. [7]  
Urinary concentration of prostanoids was calculated from the area ratio of the 
ion peaks of the 8-iso-PGF2α over the respective deuterated standard (8-iso-
PGF2α-d4). The estimated values were corrected for the urinary creatinine 
levels and expressed as picogram per milligram of creatinine. Creatinine was 
measured by standard method in the clinical laboratory of Centro Cardiologico 
Monzino using the Jaffe reaction. 
 
Vitamin E  
Plasma α- and γ-tocopherol were measured by HPLC (ESA Bioscences, 
Chelmford, MA, USA) equipped with fluorimetric detector FP-1520 (Jasco, 
Tokyo, Japan), after organic extraction as previously described [8]. 
 
 
NO pathways 
Simultaneous determination of plasma Arginine, ADMA and SDMA was 
performed by LC-MS/MS as previously described [9]. 
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Statistical analysis 
Continuous variables are summarized as mean ± 95% confidence intervals (CIs) 
if normally distributed; in case they were not normally distributed, they were 
Log-transformed before analysis. Categorical variables are summarized as 
frequency and percentage, and compared among groups by chi-square or Fisher 
exact test, as appropriate. Plasma biomarkers of oxidative balance and of NO 
pathway were firstly compared between Controls and patients candidate to 
surgery (CABG, Aortic, Mitral groups together) by general linear models 
(GLM). Three models were employed, with different levels of adjustment: 
model 1, unadjusted; model 2, adjusted for age and gender; model 3, adjusted 
for age, gender, BMI, hyperglycaemia, dyslipidemia, hypertension and treatment 
with anti-platelets, anti-hypertensive, nitrates and statins. The same models were 
employed to test the differences within the three groups of patients candidate to 
surgery. All the variables which yielded a significant p-value for ANOVA 
(three-group comparison) underwent a post-hoc analysis to test individual 
between-group differences.  
We then analyzed the overall ‗pattern‘ of oxidative balance and of NO pathway 
markers by including all ten variables (Table 2 and 3) in a principal component 
analysis (PCA). PCA is a statistical dimension-reduction technique widely 
employed to ‗compress‘ a large sets of variables in few components (linear 
functions of the variables) which convey a large proportion of the information 
contained in the original data. We used the first two principal components to 
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plot the reciprocal distances of the four groups of subjects, in terms of oxidative 
balance and of NO pathway markers, in a bi-dimensional graph.  
All tests were two-sided and p values <0.05 were considered as significant. All 
analyses were performed by SAS v. 9.2. 
 
RESULTS 
Patients. As expected, patients groups were sensibly different in terms of 
preoperative clinical features (Table 1). This reflects the different natural history 
of the coronary, aortic and mitral valve diseases. Briefly, Mitral patients were 
the youngest whereas aortic patients were the oldest; CABG patients, were more 
frequently male gender, hypertensive and dyslipidemic. As expected, also drug 
regimens were sensibly different in patient populations, CABG patients 
receiving more frequently, statins, antiplatelet and anti-hypertensive drugs, 
followed by Aortic group. 
Oxidative stress. Oxidative stress was significantly higher in patients candidate 
to surgery with respect to Controls (Table 2): the ratio between reduced and 
oxidized glutathione was higher in Controls, whereas  urinary isoprostanes were 
lower. The analysis of the behavior of these markers in surgical candidates 
(Table 3) showed no differences among groups in urinary isoprostanes; on the 
other hand, GSH/GSSG ratio was lower in Mitrals versus both CABG and 
Aortic groups, suggesting increased impairment of the glutathione pathway in 
these patients. Figure 1 summarizes the behavior of these markers. 
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Antioxidants. Plasma α-tocopherol, γ-tocopherol, and GSH/Hb were higher in 
Controls with respect to  patients scheduled for surgery (Table 2); no differences 
were detected in antioxidant markers related to the type of surgery (Table 3). 
Figure 2 outlines the antioxidant features in the different groups.  
Nitric oxide pathways. Arginine levels, as well as SDMA levels and the ratio 
between arginine and SDMA did not differ between Controls and Patients; on 
the other hand, ADMA levels were increased in candidates to surgery, and there 
was also a trend towards a lower ratio between arginine and ADMA in these 
patients  (Table 2). Interestingly, both Arg/ADMA and Arg/SDMA ratio were 
lower in in Mitral patients with respect to CABG and Aortic groups, suggesting 
some degree of impairment of nitric oxide pathways for these patients (Table 3). 
Figure 3 reports the behavior of ADMA and of Arg/ADMA and Arg/SDMA 
ratios. 
Principal component analysis. Figure 4 shows the location of the four groups 
in the plain defined by the two first principal components. The first principal 
component is positively correlated with antioxidant defences (mainly GSH) and 
with arginine, and negatively correlated with GSSG and ADMA; the second 
component is also positively correlated with antioxidant defences (mainly Vit. 
E), but is negatively correlated with arginine and positively with SDMA. 
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DISCUSSION 
In recent years basic and clinical research has underscored the main role of 
oxidative stress in cardiovascular disease. Enhanced production or attenuated 
degradation of reactive oxygen species affect endothelial and vascular function, 
and may contribute to atherosclerosis progression. Nitric oxide, released by 
normal endothelium, is one of the main determinants of normal endothelial and 
vascular function. It has been shown that cardiovascular risk factors can promote 
an imbalance between endogenous oxidants and antioxidants resulting in 
oxidative stress, impaired nitric oxide pathways function and, eventually, 
vascular dysfunction. The combination of oxidative stress and nitric oxide 
pathways imbalances may ultimately contribute to clinical cardiovascular events 
[10]. Previous studies have widely addressed the problem on oxidative stress in 
atherosclerosis and in coronary artery disease, suggesting that oxidative stress 
could even be considered as an unifying mechanism for many cardiovascular 
risk factors [11], and that a vicious circle between oxidative stress and 
inflammation can occur not only in the diseased arterial wall, where it causes 
loss of anti-oxidant protection and cell death, but also in adipose tissues, 
impairing adipocyte maturation and ultimately favoring insulin resistance [12].    
Much less is known concerning the role of oxidative stress and of nitric oxide 
pathways in valve diseases; concerning the most frequent valve disease 
eventually leading to surgery, nonrheumatic calcific aortic stenosis, several 
studies have addressed the role of localized (within the diseased aortic valve 
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itself) oxidative stress documenting that it is increased in calcified areas of 
stenotic aortic valve [13], reactive oxygen species favor aortic valve 
calcification [5], and that uncoupled nitric oxide synthase activity may also 
contribute to and exacerbate oxidative stress [13]. But very limited evidence is 
available on systemic, circulating markers of both oxidative stress and nitric 
oxide pathways derangements. Ochoa and coll. studied 11 candidates to 
coronary bypass and aortic valve surgery showing that plasma levels of 
thiobarbituric acid reactive substances, α-tocopherol, coenzyme Q and retinol 
were similar [14]; more recently, Ferrari and coworkers showed similar levels of 
ADMA and of homocysteine in healthy controls and in patients with calcific 
aortic stenosis scheduled for surgery [15]. 
If we consider the second most frequent valve disease of the adult, mitral valve 
regurgitation, current evidence is even more limited; only one paper dating back 
to 1985 has documented increased malondialdheyde levels in myxomatous 
mitral disease at echocardiography [16], and few animal studies have 
documented that a certain degree of oxidative stress may occur, both at a 
systemic and at a local level [17]. 
Our study was then designed to answer two main questions: a) first, do patients 
who are ready  and need surgery for coronary, aortic and mitral disease differ 
with respect to control patients with cardiovascular risk factors in terms of 
oxidative stress and nitric oxide impairment?; b) second, are there differences 
related to the three main adult cardiac surgical pathologies? We selected all 
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comers for an elective isolated surgical procedure (associated procedures such as 
CABG plus valve were not enrolled) to try to give the most precise picture of 
the different diseases.  
Data from our study clearly show that patients who are candidates to the most 
frequent cardiac surgical procedures of the adult have increased oxidative stress 
markers and reduced antioxidant levels with respect to controls, and this is 
paralleled by an increase of ADMA levels that suggest an 
impairment/interference in the production and release of nitric oxide. In other 
words, patients who require prompt cardiac surgery have increased impairment 
of these pathways with respect to patients who have cardiovascular risk factors 
but who are not candidates to surgery nor they had previous major 
cardiovascular events. 
Second, there are some clear differences between the surgical pathologies, but 
also some similarieties; interestignly, no differences at all could be documented 
in any of the studied variables concerning CABG and Aortic groups, either for 
the analysis of data without any adjustment or after adjustment for baseline 
differences in patient populations. This suggests that it is possible that the 
similarities between coronary disease and aortic valve disease may predominate 
on dissimilarities [18], determining a similar impairment of these pathways 
whose role in cardiovascular disease progression is still probably overlooked. 
On the other hand, the assessment of the behavior of the markers in Mitral 
patients suggests that these patients have both more marked oxidative stress with 
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respect to CABG and Aortic groups, and –especially- a more pronounced 
impairment of nitric oxide generation, a suggested by lower Arg/ADMA and 
Arg/SDMA ratios, suggesting a more marked unbalance favoring inhibitors of 
nitric oxide production and,  as a consequence, a potentially higher degree of 
endothelial dysfunction. This is an unexpected finding, as the baseline clinical 
features of Mitral patients, who were younger (notably, their mean age was 
comparable to that of Controls) and had lower incidence of cardiovascular risk 
factors with respect to CABG and aortic groups, did not anticipated a possible 
worse scenario for these patients, at least in terms of oxidative stress and of 
nitric oxide. And these differences persisted even after the adjustment for 
baseline clinical features, confirming the robustness of these data.  A possible 
explanation of this finding is currently lacking; we might speculate that it is 
possible that some differences in shear stress or in rheological features inherent 
to mitral valve regurgitation may contribute to that, as it is known that patients 
with mitral regurgitation show very striking  perturbations of regurgitant flow in 
left atrium [19]; but this remains actually only a mere hypothesis. 
This study has one main limitation, that there are several differences in baseline 
clinical features between the different patient populations. These differences 
were expected when designing this pilot study, but were accepted in order to 
gather the most reliable information concerning patients who need cardiac 
surgery for the three most frequent cardiac diseases of the adult: coronaries, 
aortic and mitral valves. And we choose to study all comers (with subsequent 
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analyses performed in order to adjust for different clinical features) instead of to 
perform a ―cherry pick‖ among candidates. 
In conclusion, our study shows that oxidative stress is increased in surgical 
candidates with respect to controls, and that Mitral patients have increased levels 
of this stress. In addition, Mitral patients have also a more pronounced 
impairment in nitric oxide generation. The molecular mechanisms underlying 
these findings as well as the possible clinical consequences have to be addressed 
in future studies.  
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Table 1 
Preoperative clinical features of the study populations 
 
Variable 
 
Controls 
 (n=33) 
CABG 
 (n=63) 
Aortic 
 (n=51)  
Mitral 
 (n=51) 
pvalue 
 
Age (years) 59 (55.2,62.8) 64 (62.0,66.0) 68 (66.1,69.9) 60 (57.0,63.0) <0.001 
Male gender 22 (66.7%) 60 (95.2%) 29 (56.9%) 32 (62.7%) <0.001 
Heigth (cm) 168 (165,171) 172 (170,174) 167 (165,169) 172 (169,175) manca 
Weight (kg) 77 (71.9,82.1) 80 (77.0,83.0) 74 (70.2,77.8) 74 (70.4,77.6) 0.034 
Diabetes (%)  3 (9.1%) 16 (25.4%) 10 (19.6%) 5 (9.8%) 0.21 
Diet-controlled 0 1 (1.6%) 1 (2.0%) 0 
 Non-insulinde pendent 3 (9.1%) 14 (22.2%) 9 (17.6%) 4 (7.8%) 
 Insulin-dependent 0 1 (1.6%) 0 1 (2.0%) 
 Hypertension (%) 16 (48.5%) 43 (68.3%) 31 (60.8%) 18 (35.3%) 0.007 
Dyslipidemia (%) 16 (48.5%) 46 (73%) 28 (54.9%) 28 (54.9%) 0.042 
Triglycerides (mg/dL) 113 (97.3,129) 131 (110,152) 104 (87.8,120) 98 (86.7,109.3) 0.09 
HDL-cholesterol (mg/dL) 55 (49.5,60.5) 43 (40.8,45.2) 53 (49.2,56.8) 52 (48.2,55.8) <0.0001 
LDL-cholesterol (mg/dL) 139 (127,151) 114 (105,123) 121 (112,130) 137 (126,148) 0.007 
Total cholesterol (mg/dL) 216 (203,229) 182 (172,192) 196 (186,206) 210 (197,223) 0.0006 
Preoperative creatinine (mg/dL) 0.83 0.93 0.86 0.88 0.09 
Preoperative glucose (mg/dL) 106 (98.8,113) 121 (112,130) 115 (108,122) 107 (102,112) 0.015 
Current smoker (%) 6 (18.2%) 13 (20.6%) 3 (5.9%) 7 (13.7%) 0.011 
Echocardiographic EF (%) 62 (58.2,65.8) 59 (56.5,61.5) 60 (57.5,62.5) 63 (60.3,65.7) 0.07 
Previous stroke (%) 0 2 (3.3%) 0 2 (3.9%) 0.38 
Previous TIA (%) 0 3 (4.8%) 1 (2.0%) 1 (2.0%) 0.54 
Drug terapie 
Antiplatelets (%) 2 (6.1%) 43 (68.3%) 19 (37.3%) 5 (9.8%) <0.0001 
Angiotensin receptor blockers (%) 4 (12.1%) 11 (17.5%) 16 (31.4%) 5 (9.8%) 0.001 
Converting enzyme inhibitors (%) 6 (18.2%) 22 (34.9%) 11 (21.6%) 18 (35.3%) 0.15 
Beta-blockers (%) 2 (6.1%) 41 (65.1%) 17 (33.3%) 21 (41.2%) <0.0001 
Calcium channel blockers (%) 3 (9.1%) 19 (30.2%) 14 (27.5%) 2 (3.9%) 0.001 
Nitrates (%) 
 
19 (30.2%) 2 (3.9%) 2 (3.9%) <0.0001 
Statins (%)  6 (18.2%) 42 (66.7%) 17 (33.3%) 9 (17.6%) <0.0001 
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Table 2 
Oxidative stress markers. antioxidants and nitric oxide pathways. 
Controls vs. Patients candidates to surgery 
 
Variable Model Controls (n=33) Patients (n=165) pvalue 
Log GSH/GSSG ratio 
1 3.19 (2.95. 3.43) 2.70 (2.60. 2.80) <.001 
2 3.19 (2.95. 3.43) 2.70 (2.60. 2.80) <.001 
3 3.35 (3.09. 3.61) 2.68 (2.58. 2.78) <.001 
Log 8-isoPGF2
(pg/mg creatinine) 
1 4.79 (4.63. 4.95) 5.18 (5.10. 5.26) <.001 
2 4.80 (4.64. 4.96) 5.17 (5.09. 5.25) <.001 
3 4.80 (4.62. 4.98) 5.18 (5.10. 5.26) <.001 
-Tocopherol 
(µg/mL) 
1 14.1 (13.1. 15.0) 11.9 (11.5. 12.3) <.001 
2 13.9 (13.0. 14.9) 11.9 (11.5. 12.4) <.001 
3 13.5 (12.5. 14.5) 12.1 (11.6. 12.4) 0.0068 
Log -Tocopherol 
(pg/mL) 
1 2.45 (2.33. 2.57) 2.03 (1.97. 2.09) <.001 
2 2.43 (2.31. 2.55) 2.04 (1.98. 2.10) <.001 
3 2.40 (2.26. 2.54) 2.04 (1.98. 2.10) <.001 
GSH/Hb 
(µmol/g Hb) 
1 7.59 (7.29. 7.89) 6.96 (6.66. 7.26) 0.10 
2 7.62 (6.90. 8.34) 6.95 (6.65. 7.25) 0.090 
3 7.98 (7.22. 8.74) 6.90 (6.60. 7.20) 0.011 
Arginine  
(µmol/L) 
1 84.4 (75.7. 93.1) 83.5 (79.2. 87.9) 0.86 
2 82.3 (72.6. 91.9) 84.1 (79.6. 88.5) 0.75 
3 81.7 (70.4. 93.0) 84.1 (79.5. 88.7) 0.72 
ADMA  
(µmol/L) 
1 0.43 (0.39. 0.47) 0.49 (0.4. 0.51) 0.010 
2 0.43 (0.39. 0.47) 0.49 (0.47. 0.51) 0.018 
3 0.41 (0.37. 0.45) 0.49 (0.47. 0.51) 0.0076 
SDMA  
(µmol/L) 
1 0.38 (0.34. 0.42) 0.41 (0.39. 0.43) 0.33 
2 0.41 (0.37. 0.45) 0.40 (0.38. 0.42) 0.70 
3 0.42 (0.36. 0.48) 0.40 (0.38. 0.42) 0.55 
Arg/ADMA ratio 
1 202 (181. 223) 175 (165. 186) 0.024 
2 197 (174. 221) 176 (166. 187) 0.12 
3 202 (176. 228) 175 (165. 186) 0.075 
Arg/SDMA ratio 
1 230 (200. 260) 215 (200. 230) 0.37 
2 212 (180. 245) 219 (204. 234) 0.70 
3 210 (173. 248) 219 (204. 234) 0.68 
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Table 3 
Oxidative stress markers. antioxidants and nitric oxide pathways. 
Surgical candidates (CABG vs. Aortic vs. Mitral) 
Variable Model CABG (n=63) Aortic (n=51) Mitral (n=51) p-value 
Log GSH/GSSG ratio 
1 2.84 (2.68.3.00)
##
 2.73 (2.55.2.91) 2.51 (2.33.2.69) 0.026 
2 2.83 (2.65.3.01)
#
 2.74 (2.54.2.94) 2.51 (2.31.2.71) 0.058 
3 2.87 (2.67.3.07) 
##
 2.80 (2.60.3.00)
 ##
 2.42 (2.22.2.62) 0.008 
Log 8-  
(pg/mg creatinine) 
1 5.14 (5.02.5.26) 5.26 (5.12.5.40) 5.13 (4.99.5.27) 0.32 
2 5.18 (5.04.5.32) 5.21 (5.07.5.35) 5.13 (4.99.5.27) 0.73 
3 5.19 (5.03.5.35) 5.21 (5.05.5.37) 5.14 (4.96.5.32) 0.83 
-Tocopherol 
(µg/mL) 
1 11.4 (10.7.12.0) 12.1 (11.4.12.9) 12.3 (11.5.13.1) 0.15 
2 11.5 (10.8.12.2) 12.1 (11.3.12.9) 12.1 (11.3.12.9) 0.42 
3 11.9 (11.0.12.7) 11.9 (11.1.12.7) 11.9 (11.1.12.8) 1.00 
-Tocopherol 
(pg/mL) 
1 1.99 (1.91.2.07) 2.11 (2.01.2.21) 2.02 (1.92.2.12) 0.18 
2 2.01 (1.93.2.09) 2.10 (2.00.2.20) 2.01 (1.91.2.11) 0.34 
3 2.04 (1.94.2.14) 2.09 (1.99.2.19) 1.98 (1.86.2.10) 0.41 
GSH/Hb 
(µmol/g Hb) 
1 7.10 (6.58.7.62) 6.71 (6.13.7.29) 7.01 (6.45.7.57) 0.58 
2 7.15 (6.61.7.69) 6.56 (5.96.7.16) 7.10 (6.50.7.70) 0.30 
3 7.05 (6.41.7.69) 6.74 (6.10.7.38) 7.13 (6.47.7.79) 0.66 
Arginine  
(µmol/L) 
1 83.8 (76.7.90.9) 89.5 (80.6.98.3) 78.7 (71.0.86.5) 0.19 
2 86.5 (78.9.94.0) 87.9 (78.7.97.0) 76.7 (68.9.84.5) 0.10 
3 89.8 (80.2.99.5) 87.4 (77.8.97.0) 73.1 (63.4.82.8) 0.053 
ADMA  
(µmol/L) 
1 0.45 (0.43.0.47) 
##
 0.50 (0.46.0.54) 0.52 (0.48.0.56) 0.005 
2 0.46 (0.42.0.50) 
##
 0.49 (0.45.0.53) 0.52 (0.48.0.56) 0.031 
3 0.48 (0.44.0.52) 0.49 (0.45.0.53) 0.50 (0.46.0.54) 0.86 
SDMA  
(µmol/L) 
1 0.39 (0.37.0.41) 0.40 (0.36.0.44) 0.43 (0.39.0.47) 0.35 
2 0.38 (0.34.0.42)
 #
 0.40 (0.36.0.44) 0.43 (0.39.0.47) 0.11 
3 0.39 (0.35.0.43) 0.40 (0.36.0.44) 0.43 (0.39.0.47) 0.46 
Arg/ADMA ratio 
1 190 (174.205) 
## 
 180 (160.200)
 #
 154 (137.171) 0.011 
2 192 (175.208) 
##
 182 (162.202) 
#
 150 (133.167) 0.003 
3 192 (171.212) 
#
 181 (161.202)
 #
 151 (130.171) 0.032 
Arg/SDMA ratio 
1 225 (201.249)  231 (201.261) 
#
 191 (165.217) 0.077 
2 235 (211.260) 
##
 227 (197.257) 
#
 182 (156.207) 0.008 
3 239 (207.270) 
#
 226 (194.258) 
#
 178 (147.210) 0.036 
 
#=p < 0.05vs. Mitral 
 ## =p < 0.01 vs. Mitral 
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4.2  New surgical techniques and oxidative stress: is there any link 
possible ? 
 
In the recent years all the community of cardiac surgeons reached the convinction that 
preserve as much tissue as possible (―Respect rather than resect‖ philosophy) is fundamental 
to achieve the best results in terms of morbility, mortality and outcomes in the field of  heart 
valve surgery. 
Therefore, in the light of the fact that sparing the patient‘s own subvalvular apparatus the left 
ventricle in known to perform more efficiently, some cardiac surgeon are proposing new 
techniques that should improve the long term outcomes of the procedure. 
Furthermore, the implication of the oxidative stress in the degeneration of the native heart 
valves and in the failure of the aortic and mitral valve repair is a field still under study that 
may have several pratical  implication. 
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As illustrated in the above cartoon, the mechanic stress due to chordal rupture in mitral valve 
prolapse leads to the activation of several biometabolic pathways that, in the end, bring to an 
increased oxidative stress at cellular level and finally to endothelial disfunction. 
Similarly, the correction of the defect using surgical techniques that tend to stretch the leaflet 
and the papillary muscles may lead to the same oxidative stress activation and, in the end, to 
the failure of the valvuloplasty. 
Personally, I have developed new techniques briefly described below that allowing more 
physiologic transvalvular flow should reduce the mechanic stress to the ventricle and finally 
optimize the surgical repair. 
 
 Tent-shape technique: another procedure to repair P2 of 
posterior leaflet of mitral valve 
 
 
 
 
 
 
 
 
 
  Fig. 2. The Gore-Tex suture is tied onto a strip of 
pericardium after an estimation of the chord length (point 
A). The two arms of the 4/0 Cardionyl suture are then 
passed through the thickened P2 free edge and knotted 
over a pledget of pericardium. 
Fig. 1. The new chord is attached to the suitable papillary 
muscle. Many loose reverse knots are tied (making small 
loops) so that the whole length of the knots reaches the 
mid expected length of the new chord. The two needles 
are passed through the body of P2 from the ventricular to 
the atrial side at the same height of non-prolapsing P1 
and P3 of the posterior leaflet (point A). The anchor for 
the edge of the excess portion of P2 (point B) is 
determined on the new chord. One suture of 4/0 
Cardionyl is inserted in the appropriate small loop. 
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An accurate valve analysis is performed: the P2 height is assessed, the ruptured or redundant 
chords are identified, and papillary muscles are inspected to identify the suitable muscle for 
chordal attachment. To facilitate visualization of the subvalvular apparatus, the elongated 
chordae of P2 can sometimes be resected. Thereafter, the two needles of a 5/0 
polytetraflouroethylene (Gore-Tex,W.L. Gore & Associates, Newark, Delaware, USA) suture, 
sup- ported by a felt pledget, are passed through the tip of the appropriate papillary muscle 
with a forehanded technique, so the new chord arises from the papillary side that faces the 
posterior ventricular wall. The Gore-Tex is tied loosely. Then, many loose reverse knots are 
tied (making small loops), as it is required that the whole length of the knots reaches the mid-
expected length of the new chord. The length of second- or third-order chordae of the non-
prolapsing portion of P2 or the non-prolapsing A2 of the anterior leaflet can be used as a 
reference point to measure the expected length of the new chord. The two needles are 
subsequently passed through the body of P2 from the ventricular to the atrial side at the same 
height of non-prolapsing P1 and P3 of the posterior leaflet (point A, Fig. 1). The suture is left 
untied. The appropriate length of the new chord is estimated by injection of saline solution 
into the left ventricular cavity with a considerable pressure. The Gore-Tex suture is then tied 
onto a strip of pericardium, maintaining both the edge of the anterior leaflet (A2) and the 
point A (the anchor for the new chord in the body of P2) at the same level. Next, the anchor 
for the edge of the excess portion of P2 (point B, Fig. 1) is determined on the new chord (one 
of the multiple small loops). The distance between the anchor for the edge of P2 (point B) and 
the anchor for the new chord on the leaflet (point A) should be equal to or less than the length 
of the excess portion of P2. In addition, in case of high risk of SAM, it is advisable that the 
anchoring for the P2 edge on the new chord should be toward the papillary muscle. One 
suture of 4/0 Cardionyl is inserted in the appropriate small loop (anchor for the edge of P2; 
point B, Fig. 1) and tightly tied. The two arms of the suture are then passed through the 
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thickened P2 free edge and knotted over a pledget of pericardium (Fig. 2). Valve competency 
is then checked by fluid testing. The repair procedure is completed by implantation of the 
annuloplasty ring of choice. 
 
 Annulus-edge-papillary stitch to repair P2 of the mitral valve 
posterior leaflet 
 
Transesophageal echocardiography is performed, and cardiopulmonary bypass is established. 
Antegrade and retrograde cold-blood cardioplegia, CO2 insufflation of the operative field, 
and moderate hypothermia (32_C) are routinely used. The valve is inspected, and after 
confirmation of the prolapsing P2, a pair of 5-0 polytetrafluoroethylene (Gore-Tex, WL Gore 
& Associates, Inc, Newark, DE) sutures are passed through a pledget and the posterior MV 
annulus from the atrial to the ventricular side at the site corresponding to the tip of the 
prolapsing P2. A non-sliding knot is then tied on the ventricular side (Figure 1, A). The 2 
arms of the sutures are passed through the thickened P2 free edge from the ventricular to the 
atrial side and tightly knotted on the atrial surface (Figure 1, A). Thereafter, the 2 needles are 
passed through the tip of the appropriate papillary muscle with a backhanded technique and 
then through an expanded polytetrafluoroethylene pledget without tying (Figure 1, B, C). 
Thus, the new chord has an obtuse angle formed by a vertex (the P2 edge ) and 2 rays: the 
edgepapillary (E-P suture) and edge-posterior annulus (E-A suture). By using the 
nonprolapsed anterior leaflet as a guide, the length of the E-P component is determined, 
taking into consideration that it should be shorter than the non-prolapsing chord to bring down 
the excessive portion of P2 into the ventricular cavity. A metal clip is placed across the 2 arms 
of the E-P suture ahead of the expanded polytetrafluoroethylene pledget. The valve is tested 
by injecting cold saline into the ventricular cavity, and the valvular competence is determined 
by the length of the E-P component. The 2 arms are then tied tightly against the clip, which is 
removed and cut (Figure 1, D).  
 118 
 
 
 
The annuloplasty ring is sized according to the height of the well-stretched anterior leaflet, 
and a slightly oversized ring is inserted into the mitral annulus with interrupted horizontal 
mattress sutures of 2-0 Polydek, being careful to keep free the pledget of the untied atrial E-P 
suture (annular chordal anchor) behind the ring‘s mid-posterior portion (Figure 1, E). Once 
the ring is in its definitive position, the valve is again tested by injecting cold saline with 
considerable pressure (Figure 1, E). The height of the P2 is controlled by the E-A 
component‘s length, so the untied atrial suture behind the ring is carefully pulled to decrease 
the height of P2 (Figure 2, A), allowing the A2 of the anterior leaflet to occupy its space on 
the radial direction of the valvular area until the MV regains its smileshape and the first slight 
insufficiency appears, while both the left ventricle and leaflets are distended under the filling 
pressure (Figure 2, B). A metal clip is engaged across the 2 arms behind the mid-posterior 
portion of the ring. The 2 arms are then tied tightly against the clip and cut. The clip is 
FIGURE 1. A, Pair of 5-0 
polytetrafluoroethylene (Gore-Tex; WL Gore 
& Associates, Inc, Newark, DE) sutures are 
passed through the posterior MV annulus from 
the atrial to the ventricular side at the site 
corresponding to the tip of the prolapsing P2. 
A non-sliding knot is tied on the ventricular 
side. The 2 arms of the sutures are passed 
through the thickened P2 free edge from the 
ventricular to the atrial side and tightly 
knotted to anchor the P2 edge into the new 
chord. B, The 2 needles are passed through 
the tip of the papillary muscle with a 
backhanded technique and then through an 
expanded polytetrafluoroethylene pledget 
without tying. Thus, the new chord arises from 
the papillary side that faces the posterior 
ventricular wall. C, AEP stitch as seen by the 
surgeon‘s assistant. D, Cross-profile shows 
that the length of the E-P component is 
determined by saline injection test. E, Slightly 
oversized ring is inserted into the mitral 
annulus with interrupted horizontal mattress 
sutures. The pledget of the untied atrial E-P 
suture behind the ring is free. Another saline 
injection test is performed with considerable 
pressure once the ring is in its definitive 
position. The valve is continent but 
anatomically abnormal (sadshape). 
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removed. If the P2 is high and wide with a notable shape of a square, rectangle, or trapezoid, 
more than 1 AEP stitch should be made with the same technique (Figure 2, C). In cases with a 
high risk of systolic anterior motion, for example, a small left ventricular cavity or redundant 
anterior leaflet, and before repairing the MV with the AEP stitch, the P2 can be remodeled by 
a small triangular-shaped resection with the apex toward the annulus (Figure 2, D, E). 
Since August 2010, we have applied the AEP stitch technique in 5 patients with severe MV 
regurgitation caused by isolated prolapse of a high P2 with excellent results.  
 
 Papillary muscle–to–anterior annulus stitches: Another 
technique to prevent systolic anterior motion after mitral valve 
repair 
 
     
The inspection of the mitral valve is carried out as usual. The leaflets are accurately analyzed, 
and the papillary muscles are inspected to identify the posterior head of each papillary 
muscle. A double-armed 4-0 polytetrafluoroethylene (Gore-Tex;W. L. Gore & Associates, 
Flagstaff, Ariz) suture supported by a felt pledget is passed twice through the tip of the 
posterior head of the posterior papillary muscle with a forehand technique and is fixed with a 
loose knots to avoid necrosis. The ventricular surface of the anterior leaflet is inspected with 
two nerve hooks to explore the attachment of  secondary chord, which arises from the 
posterior papillary muscle (preferably the most distant from the leaflet‘s board, and toward 
the mitral anteroposterior axis). The height of the selected chord is used as a guide for 
determining the length of the first part of the new chord. A metal clip is placed across the 2 
arms of the new chord at the level of the anchor of the stretched native chord selected. The 
trace of the attachment of the selected chord on the atrial surface of the anterior leaflet is 
determined by insertion of a thin insulin needle as a marker beside the attachment‘s site.  
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Thereafter, the anterior leaflet is once again pulled down into the ventricular cavity, leaving 
the insulin needle in place. On the atrial surface of the anterior leaflet, the distance between 
the marker (the insulin needle) and the anterior annulus determines the length of the second 
part of the new chord, which will be anchored to the anterior annulus with no excessive 
tension during the presystolic phase. Multiple knots are then tied against the metal clip until 
the whole length of the knots corresponds to the distance between the marker and midanterior 
mitral annulus. Subsequently, the clip is removed. Thereafter the anterior leaflet is pulled up 
to maximum with a nerve hook, and the insulin needle is gently removed from the anterior 
leaflet. The 2 arms of the suture are then passed through approximately the middle of the 
anterior mitral leaflet from the ventricular to the atrial surface side by means of a backhand 
technique, and the suture is left untied.  
 
FIGURE 1. A, A double-armed 4-0 polytetrafluoroethylene 
(Gore-Tex;W. L. Gore & Associates, Flagstaff, Ariz) suture 
is passed twice through the tip of the posterior head of the 
posterior papillary muscle with a forehand technique. The 
new chord thus arises from the papillary side that faces the 
posterior ventricular wall. The surgeon‘s assistant uses a 
nerve hook to stretch the second chord selected. The length 
of the selected chord is used as a guide to determine the first 
part of the new chord. A metal clip is engaged across the 2 
arms at the level of the attachment of the stretched native 
chord. B, Cross-profile illustration shows a thin insulin 
needle inserted from the ventricular to the atrial side through 
the anterior leaflet in the site of native chordal attachment. 
The distance from the marker to the anterior annulus 
determines the length of the second part of the new chord. 
Multiple knots have been tied against the metal clip. The 
whole length of the knots should correspond to the distance 
between the marker and midanterior mitral annulus, which is 
equal to the distance between the chordal attachment and the 
anterior annulus. C, The 2 arms of the suture are then passed 
through at about the midanterior mitral leaflet from the 
ventricular to the atrial surface side by means of a backhand 
technique, taking care not to injure the aortic valve. The 
surgeon thus cannot see the point of entry. D, Cross-profile 
Illustration represents the anterior ring in its definitive 
position. The marker has been removed. The needles of the 
atrial side of the Gore-Tex sutures are passed through the 
anterior prosthetic sheath. 
 121 
 
 
 
The procedure is repeated step by step to implant the second papillary muscle–anterior 
annulus chord, which arises from the posterior head of the anterior papillary muscle and is 
anchored to about the middle of the anterior mitral annulus. Subsequently, the surgeon 
continues the mitral repair, choosing the appropriate strategies for the lesions of the valve 
identified during the valve analysis. In our 4 selected cases, the posterior leaflet repair was 
performed with a traditional triangular resection. Finally, an annuloplasty Physio ring 
(Physio-Control, Inc, Redmond, Wash) is sized and added to complete the repair, maintaining 
free the untied Gore-Tex sutures outside the ring. When the ring is in its final position, the 
Gore-Tex sutures are passed through the anterior prosthetic sheath and tightly knotted. After 
fluid testing to confirm the valve‘s competence, the atrium is once again closed. 
 
FIGURE 2. A, Cross-profile 
illustration shows the second 
papillary muscle–to–anterior annulus 
stitch, which arises from the posterior 
head 
of the anterior papillary muscle. The 
2 new chords are tightly tied onto the 
prosthetic sheath. B, Illustration of 
the final position of the 2 papillary 
muscle–to–anterior annulus stitches 
as they would be seen by the surgeon 
if the anterior leaflet were 
transparent. 
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In conclusion we can affirm that new surgical skills and techniques are required in order to 
perform procedures that can lead to more physiological repair of the heart valves; this might 
have a clinical and pratical implications. 
Further studies are necessary to improve our knowledge about the role of oxidative stress in 
the outcome of cardiac valve repair. 
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5. Conclusions 
 
In the last two decades we faced a huge changing in thinking about heart valve pathology and 
surgical treatment. The development of new knowledge about the cellular mechanisms of 
damage may let us understand the intrinsic pathophysiology of the degenerative process that 
leads to the aortic and mitral valve degeneration and lost of function. In particular, as 
described in this work, oxidative stress seems to play a central role in this degenerative 
process and so medical and surgical options that can improve the cellular and tissutal response 
to the free oxygen radicals are expected to ameliorate the clinical outcome. 
From the pratical point of view, the application of the knowledge arosen from the 
―translational research‖, i.e. that branch of the research who could quickly applied in clinical 
practice, may leads to the progression of new and more efficient treatment‘s modality. 
The concepts of  ―respect rather than resect‖ and the development of new surgical techniques 
are emerging to put the surgical treatment of valve disease closer to the normal physiology of 
the cardiac valves.  
More studies, in particular those analyzing the results of these new and more conservative 
techniques are required to confirm the promising initial results.     
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